The International Diabetes Closed Loop (iDCL) trial: 1 
Clinical Acceptance of the Artificial Pancreas  in 2 
Pediatrics  3 
A Study of t:slim X2 with Control -IQ Technology   [ADDRESS_527535] University, [LOCATION_004]  16 
Yale University, Connecticut  17 
Coordinating Center  18 
Jaeb Center for Health Research  19 
 20 
 21 
 22 
  Version Number: v2.5 23 
May 2 4, 2019  24 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 2 OF 76 
 KEY ROLES  25 
 
Sponsor  Chair / IDE Chair   
Name, degree  Marc Breton  
Institution Name  [CONTACT_199562], Center for Diabetes Technology  
  
Protocol Chair/Director   
Name, degree  R. Paul Wadwa, MD  
Institution Name  [CONTACT_418106], University of Colorado  
 
JCHR Coordinating Center Director   
Name, degree  Katrina Ruedy, MSPH  
Institution Name  [CONTACT_418107], degree  Roy Beck, M.D., Ph.D.  
Institution Name  [CONTACT_352741]  
 26 
  27 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 3 OF 76 
 PROTOCOL VERSION HISTORY  28 
Version 
Number  Author(s)  Approver  Effective 
Date  Revision Description  
1.0 R. Paul Wadwa  
Daniel Cherñavvsky  
Katrina Ruedy  
Roy Beck  R. Paul Wadwa  15NOV 2018  Original protocol.   
1.1 Jessica Rusnak  Daniel 
Cherñavvsky  21NOV2018   
1.2 Sarah Borgman  Katrina Ruedy  28NOV2018   
2.0 Mary Oliveri  Daniel 
Cherñavvsky  10DEC2018  Modified study design to include extension phase 
to the experimental group  
2.1  Katrina Ruedy  Daniel 
Cherñavvsky  20Dec2018  Clarifications added for consistency throughout 
protocol  
2.2 Jessica Rusnak  Daniel 
Cherñavvsky  15Jan2019  Adding inclusion  criteria  and clarification 
regarding use of Basal  IQ feature ; updated 
incorrect section references  
2.3 Jessica Rusnak  Katrina Ruedy  4Feb2019  Removing and adding questionnaires to be 
completed by [CONTACT_418086]/guardians  
2.4 Katrina Ruedy  Daniel 
Cherñavvsky  01Apr 2019  Correcting discrepancies in revised questionnaire 
descriptions  and other minor clarifications.  
2.5 Katrina Ruedy  Marc Breton  01Jun 2019  Corrections to statistical analysis chapter; update 
of Sponsor name [CONTACT_418108]ñavvsky to 
Marc Breton  
 29 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 4 OF 76 
 TABLE OF CONTENTS  30 
CHAPTER 1: BACKGROUND INFORMATION  ................................ ................................ .............................  19 31 
 Introduction  ................................ ................................ ................................ ..........................  19 32 
 Rationale  ................................ ................................ ................................ ..............................  22 33 
 Potential Risks and Benefits of the Investigational Device  ................................ .................  22 34 
1.3.1 Known Potential Risks  ................................ ................................ ................................ ... 22 35 
[IP_ADDRESS] Venipuncture Risks  ................................ ................................ ................................  22 36 
[IP_ADDRESS] Fing erstick Risks  ................................ ................................ ................................ .... 22 37 
[IP_ADDRESS] Subcutaneous Catheter Risks (CGM)  ................................ ................................ .... 22 38 
[IP_ADDRESS] Risk of Hypoglycemia  ................................ ................................ ...........................  23 39 
[IP_ADDRESS] Risk of Hyperglycemia  ................................ ................................ ..........................  23 40 
[IP_ADDRESS] Risk of Device Reuse  ................................ ................................ .............................  23 41 
1.3.1. 7 Questionnaire  ................................ ................................ ................................ .........  24 42 
[IP_ADDRESS] Other Risks  ................................ ................................ ................................ ............  24 43 
1.3.2 Known Potential Benefits  ................................ ................................ ..............................  24 44 
1.3.3 Risk Assessment  ................................ ................................ ................................ ............  24 45 
 General Considerations  ................................ ................................ ................................ ........  25 46 
CHAPTER 2: STUDY ENROLLMENT AND SCREENING  ................................ ................................ ..............  26 47 
 Participant Recruitment and Enrollment ................................ ................................ ..............  26 48 
2.1.1 Informed Consent and Authorization Procedures  ................................ ..........................  26 49 
 Participant Inclusion Criteria  ................................ ................................ ...............................  27 50 
 Participant Exclusion Criteria  ................................ ................................ ..............................  28 51 
 Screening Procedures  ................................ ................................ ................................ ...........  28 52 
2.4.1 Data Collection and Testing ................................ ................................ ...........................  28 53 
CHAP TER 3: RUN-IN PHASE  ................................ ................................ ................................ ......................  30 54 
 Run-in Phase Overview  ................................ ................................ ................................ ....... 30 55 
 Initiation of CGM  ................................ ................................ ................................ ................  30 56 
 Initiation of Pump  ................................ ................................ ................................ ................  30 57 
 Blood Glucose and Ketone Testing  ................................ ................................ .....................  31 58 
 Assessment of Successful Completion of the Run -in Phase ................................ ................  32 59 
 Optimization of Insulin Pump Settings  ................................ ................................ ................  33 60 
CHAPTER 4: RANDOMIZATION VISIT ................................ ................................ ................................ ....... 34 61 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 5 OF 76 
 
 Rand omization Visit  ................................ ................................ ................................ ............  34 62 
4.1.1 HbA1c  ................................ ................................ ................................ ............................  34 63 
4.1.2 Baseline C -Peptide Assessment  ................................ ................................ .....................  34 64 
4.1.3 Randomization  ................................ ................................ ................................ ...............  34 65 
4.1.4 Questionnaires ................................ ................................ ................................ ................  35 66 
CHAPTER 5: MAIN STUDY PROCEDURES  ................................ ................................ ................................ . [ADDRESS_527536]  ................................ ................................ ................................ .. 38 73 
5.2.5 2 -Week Visit (Training Review and Insulin Pump Optimization)  ................................  [ADDRESS_527537]  ................................ ................................ ................................ .. 39 77 
5.3.3 2 -Week Visit (Training Review and Insulin Pump Optimization)  ................................  39 78 
 Follow -up Visits and Phone Contacts for Both Groups  ................................ ......................  40 79 
5.4.1 Follow -up Visits ................................ ................................ ................................ .............  40 80 
[IP_ADDRESS] Procedures at Follow -up Visits  ................................ ................................ ..............  [ADDRESS_527538] Phase Visit  ................................ ................................ ....................  41 84 
 Early Termination Visit (If Applicable)  ................................ ................................ ..............  41 85 
 Unscheduled Visits  ................................ ................................ ................................ ..............  41 86 
 Participant Access to Study Device at Study Closure  ................................ .........................  41 87 
CHAPTER 6: EXTENSION PHASE PROCEDURES  ................................ ................................ .......................  42 88 
 Closed Loop Control Participants  ................................ ................................ ........................  42 89 
 SC Group Participants  ................................ ................................ ................................ .........  42 90 
 Early Termination Visit (If Applicable)  ................................ ................................ ..............  43 91 
 Unscheduled Visits  ................................ ................................ ................................ ..............  43 92 
 Participant Access to Study Device at Study Closure  ................................ .........................  43 93 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 6 OF 76 
 CHAPTER 7: STUDY DEVICES  ................................ ................................ ................................ ....................  44 94 
 Description of the Investigational Device  ................................ ................................ ...........  44 95 
7.1.1 Insulin Pump  ................................ ................................ ................................ ..................  44 96 
7.1.2 Continuous Glucose Monitoring  ................................ ................................ ....................  44 97 
7.1.3 Blood Glucose Meter and Strips  ................................ ................................ ....................  44 98 
7.1.4 Ketone Meter and Strips  ................................ ................................ ................................  44 99 
7.1.5 Study Device Accountability Procedures  ................................ ................................ ...... 44 100 
7.1.6 Blood Ketone Testing  ................................ ................................ ................................ .... 44 101 
 Safety Measures  ................................ ................................ ................................ ...................  44 102 
7.2.1 CGM Calibration  ................................ ................................ ................................ ...........  44 103 
7.2.2 System Failure  ................................ ................................ ................................ ...............  45 104 
7.2.3 Hypoglycemia Threshold Alert and Safety Protocol  ................................ .....................  45 105 
7.2.4 Hyperglycemia Threshold Alert and Safety Protocol  ................................ ....................  45 106 
CHAPTER 8: TESTING PROCEDURES AND QUESTIONNAIRES  ................................ ................................ . 47 107 
 Laboratory Testing  ................................ ................................ ................................ ...............  47 108 
8.1.1 Comprehensive Metabolic Panel (CMP)  ................................ ................................ ....... 47 109 
8.1.2 HbA1c:  ................................ ................................ ................................ ...........................  47 110 
8.1.3 Urine Pregnancy:  ................................ ................................ ................................ ...........  47 111 
8.1.4 C -peptide and Glucose  ................................ ................................ ................................ ... 47 112 
 Questionnaires  ................................ ................................ ................................ .....................  47 113 
8.2.1 Clarke’s Hypoglycemia Awareness Scale – Child and Parent  ................................ ...... 48 114 
8.2.2 Hypoglycemia Fear Survey (HFS -II)/Low Blood Sugar Survey – 115 
Child and Parent  ................................ ................................ ................................ ......................  48 116 
8.2.3 Problem Areas In  Diabetes Survey (PAID) – Child and Parent  ................................ .... 48 117 
8.2.4 PedsQL Diabetes Module – Child and Parent  ................................ ...............................  48 118 
8.2.5 INSPI[INVESTIGATOR_66681] – Child and Parent  ................................ ................................ .............  49 119 
8.2.6 Pi[INVESTIGATOR_2272] (PSQI) – Parent ................................ ............................  49 120 
8.2.7 System Usability Scale (SUS) – Closed -Loop participants only  ................................ ... 49 121 
CHAPTER 9: ADVERSE EVENTS , DEVICE ISSUES , AND STOPPI[INVESTIGATOR_16442]  ................................ ..............  50 122 
 Adverse Events  ................................ ................................ ................................ ....................  50 123 
9.1.1 Definitions ................................ ................................ ................................ ......................  50 124 
9.1.2 Reportable Adverse Events  ................................ ................................ ............................  51 125 
[IP_ADDRESS] Hypoglycemic Events  ................................ ................................ ............................  51 126 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 7 OF 76 
 [IP_ADDRESS] Hyperglycemic Events/Diabetic Ketoacidosis  ................................ .......................  51 127 
9.1.3 Relationship of Adverse Event to Study Device ................................ ............................  52 128 
9.1.4 Intensity of Adverse Event ................................ ................................ .............................  52 129 
9.1.5 Coding of Adverse Events  ................................ ................................ .............................  53 130 
9.1.6 Outcome of Adverse Event  ................................ ................................ ............................  53 131 
 Reportable Device Issues  ................................ ................................ ................................ ..... 54 132 
 Pregna ncy Reporting ................................ ................................ ................................ ............  54 133 
 Timing of Event Reporting  ................................ ................................ ................................ .. 54 134 
 Stoppi[INVESTIGATOR_2121]  ................................ ................................ ................................ ..................  55 135 
9.5.1 Participant Discontinuation of Study Device  ................................ ................................ . 55 136 
9.5.2 Criteria for Suspending or Stoppi[INVESTIGATOR_3396]  ................................ .......................  55 137 
 Independent Safety Oversight  ................................ ................................ ..............................  55 138 
 Risks ................................ ................................ ................................ ................................ ..... 56 139 
CHAPTER 10: MISCELLANEOUS CONSIDERATIONS  ................................ ................................ .................  57 140 
 Drugs Used as Part of the Protocol  ................................ ................................ ....................  57 141 
 Prohibited Medications, Treatments, and Procedures  ................................ .......................  57 142 
 Participant Withdrawal  ................................ ................................ ................................ ...... 57 143 
 Confidentiality  ................................ ................................ ................................ ...................  57 144 
CHAPTER 11: STATISTICAL CONSIDERATION  ................................ ................................ .........................  58 145 
 Statistical and Analytical Plans ................................ ................................ ..........................  58 146 
 Statistical Hypotheses  ................................ ................................ ................................ ........  58 147 
 Sample Size ................................ ................................ ................................ ........................  58 148 
 Outcome Measures  ................................ ................................ ................................ ............  59 149 
11.4.1 Primary Efficacy Endpoint  ................................ ................................ ..........................  59 150 
11.4.2 Secondary Efficacy Endpoints  ................................ ................................ .....................  59 151 
[IP_ADDRESS] Secondary Efficacy Endpoints Included in Hierarchical Analysis  ......................  59 152 
[IP_ADDRESS] Other Secondary Efficacy Endpoints  ................................ ................................ ... 59 153 
[IP_ADDRESS] Safety Analyses  ................................ .....................  Error! Bookmark not defined.  154 
11.4.3 CGM Metrics Calculations  ................................ ................................ ..........................  60 155 
 Analysis Datasets and Sensitivity Analyses  ................................ ................................ ...... 61 156 
11.5.1 Per Protocol Analyses  ................................ ................................ ................................ .. 61 157 
11.5.2 Other Sensitivity Analyse s ................................ ................................ ...........................  61 158 
 Analysis of the Primary Efficacy Endpoint  ................................ ................................ ....... 62 159 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 8 OF 76 
 
 Analysis of the Secondary Endpoints  ................................ ................................ ................  62 160 
11.7.1 Hierarchical Analyses  ................................ ................................ ................................ .. 62 161 
11.7.2 Other Endpoint Analyses  ................................ ................................ .............................  63 162 
 Safety Analyses ................................ ................................ ................................ ..................  64 163 
 Intervention Adherence ................................ ................................ ................................ ...... 65 164 
 Adhe rence and Retention Analyses  ................................ ................................ .................  66 165 
 Baseline Descriptive Statistics  ................................ ................................ .........................  66 166 
 Device Issues  ................................ ................................ ................................ ...................  66 167 
 Planned Interim Analyses  ................................ ................................ ................................  67 168 
 Subgroup Analyses  ................................ ................................ ................................ ..........  67 169 
 Multiple Comparison/Multiplicity  ................................ ................................ ...................  68 170 
 Exploratory Analyses  ................................ ................................ ................................ ....... 68 171 
CHAPTER 12: DATA COLLECTION AND MONITORING  ................................ ................................ ............  69 172 
 Case Report Forms and Device Data  ................................ ................................ .................  69 173 
 Study Records Retention  ................................ ................................ ................................ ... 69 174 
 Quality Assurance and Monitoring  ................................ ................................ ....................  69 175 
 Protocol Deviations ................................ ................................ ................................ ............  70 176 
CHAPTER 13: ETHICS /PROTECTION OF HUMAN PARTICIPANT S ................................ ............................  [ADDRESS_527539]  ................................ ................................ ................................ .................  71 178 
 Institution al Review Boards ................................ ................................ ...............................  71 179 
 Informed Consent Process  ................................ ................................ ................................ . 71 180 
13.3.1 Consent Procedures and Documentation  ................................ ................................ ..... 71 181 
13.3.2 Participant and Data Confidentiality  ................................ ................................ ............  71 182 
CHAPTER 14: REFERENCES  ................................ ................................ ................................ .......................  [ADDRESS_527540] OF ABBREVIATIONS  185 
ABBREVIATION  DEFINITION  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth, Bluetooth low energy  
CRF Case Report Form  
CGM Continuous Glucose Monitoring  System  
CLC Closed -Loop Control  
CSII Continuous Subcutaneous Insulin Injection  
CTR Control -to-Range  
DiAs Diabetes Assistant  
DKA Diabetic Ketoacidosis  
EC European Commission  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HbA1c  Hemoglobin A1c  
ID Identification  
iDCL International Diabetes Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin -on-Board 
IQR Interquartile Range  
JDRF Juvenile Diabetes Research Foundation  
LGS  Low Glucose Suspend  
PLGS  Predictive Low Glucose Suspend  
POC Point -of-Care 
QA Quality Assurance  
QC Quality Control  
RBM Risk-Based Monitoring  
RCT  Randomized Control Trial  
SC Standard of Care group  
SD Standard Deviation  
TDD Total Daily Dose  
UI User Interface  
 186 
187 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 10 OF 76 
 Signature [CONTACT_3490]  188 
The International Diabetes Closed Loop (iDCL) trial:  189 
Clinical Acceptance  of the Artificial Pancreas  in Pediatrics  190 
A Study of t:slim X2 with Control -IQ Technology  191 
Protocol Identifying Number: DCLP 5 Pediatrics  192 
IND/IDE Sponsor: University of Virginia  193 
Version  Number: v. 2.5 194 
24MAY2019  195 
 
Protocol Chair   
Name, Institution  R. Paul Wadwa, M.D./ University of Colorado – Barbara Davis Center  
Signature/Date   
 
Sponsor (IDE Holder)   
Name/Institution  Marc Breton / University of Virginia  
Signature/Date   
 
Coordinating Center Director   
Name, Institution  Katrina J. Ruedy, MSPH; Jaeb Center for Health Research  
Signature/Date   
 
Medical Monitor   
Name, Institution  Roy Beck, MD, PhD; Jaeb Center for Health Research  
Signature/Date   
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 11 OF 76 
 CLINICAL CENTER PRINCIPAL INVESTIGATOR [INVESTIGATOR_418069] 196 
COMPLIANCE  197 
Protocol Title:  The International Diabetes Closed Loop (iDCL) trial: Clinical Acceptance of 198 
the Artificial Pancreas in Pediatrics - A Study of t:slim X2 with Control -IQ Technology  199 
Protocol Version/Date: v2.5 / 24MAY2019  [ADDRESS_527541] read the protocol specified above.  In my formal capacity as a Clinical Center Principal 201 
Investigator, my duties include ensuring the safety of the study participants enrolled under my 202 
supervision and providing the Jaeb Center for Health Research , with complete and timely 203 
information, as outlined in the protocol.  It is understood that all information pertaining to the 204 
study will be held strictly confidential and that this confidentiality requirement applies to all 205 
study staff at this clinical center . 206 
This trial will be carried out in accordance with ICH E6 Good Clinical Practice (GCP) and as 207 
required by [CONTACT_716]: [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to 208 
clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 2 1 CFR Part 312, and/or 21 209 
CFR Part 812).  [ADDRESS_527542] (I RB), or other approved Ethics Committee, except where necessary [ADDRESS_527543](s) to the trial participants.  214 
All key personnel (all individuals responsible for the design and conduct of this trial) have [ADDRESS_527544] of this study are 217 
informed about their obligations in meeting the above commitments.  218 
Investigator’s Signature __________________________________  Date: _____ / _____ / _____  219 
 dd mmm  yyyy  220 
Investigator’s Name: ____________________________________  221 
Clinical Center Name/Number: _____________________________________  222 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 12 OF 76 
 PROTOCOL SUMMARY  223 
PARTICIPANT AREA  DESCRIPTION  
Title  The International Diabetes Closed Loop (iDCL) trial: Clinical Acceptance 
of the Artificial Pancreas in Pediatrics - A study of t:slim X2 with Control -
IQ Technology  
Précis A randomized controlled trial of at -home closed loop system vs . standard 
of care (defined as either sensor -augmented pump or any kind of  low 
predictive low  blood glucose suspend [PLGS ; LGS ] if participant is  
currently  using) in youth age 6 to 13 years  old. 
Investigational Device  t:slim X2 with Control -IQ and Dexcom G6 system  
Objectives  The objective of the study is to assess efficacy and safety of a closed loop  
control  (CLC)  system (t:slim X2 with Control -IQ Technology) in a 
randomized controlled trial  with partial crossover . 
Study Design  First phase a  16-week  parallel group randomized clinical trial with 3:[ADDRESS_527545] of 
care (SC ); followed by a 12-week period  where the  Standard of Care ( SC) 
group will transition to use CLC and the experimental arm will extend the 
use of CLC for the same period  
Number of Clinical Centers  Up to [ADDRESS_527546] phase  is time in target range 70 -180 
mg/dL measured by [CONTACT_418087]. SC group over 16 weeks  
The primary outcome for the extension phase  is improving time in range  
70-180 mg/dL by [CONTACT_418088] (control group) transition s to t:slim X2 
with Control -IQ compared with the same group during the Main Phase.   
Population  Key Inclusion Criteria  
 Type 1 Diabetes  
 Ages ≥ 6 and ≤ 13 years  old 
Key Exclusion Criteria   
 Use of any non -insulin glucose -lowering agents except metformin  
 Actively using any other closed -loop system  
Sample Size  First phase: Up to [ADDRESS_527547] of a partial crossover : All randomized 
participants  will participate in an extension phase for another 12 weeks  
(total 28 weeks ).  The SC group (control group) will crossover to use 
Tandem t:slim X2 with Control -IQ for 12 weeks . The experimental arm 
will continue on the Control -IQ for 12 weeks .   
Treatment Groups   Intervention Group: t:slim X2 with Control -IQ Technology and 
Study CGM.  
 Control Group: Standard of care ( SC) (defined as either sensor -
augmented pump or any kind of low  or predictive low  blood glucose  
suspend  [PLGS; LGS] if participant is  currently  using) , and study 
CGM  
 All participants  will be offer ed to extend the study for 12 weeks  and 
the SC group will use the t:slim X2 with Control -IQ System   after 
the first 16-week  phase   
Participant Duration  16-20 weeks  (depending on duration of run -in phase)  plus ~12-week 
extension  phase  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 13 OF 76 
 PARTICIPANT AREA  DESCRIPTION  
Protocol Overview/Synopsis  After consent is signed, eligibility will be assessed.  Eligible participants 
not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 
CGM with minimum data requirements will initiate a run -in phase of 2 to 
4 weeks that will be customized based o n whether the participant is 
already a pump or CGM user.  Participants who skip or successfully 
complete the run -in will be randomly assigned 3:1 to the use of closed -
loop control (CLC group)  system  using  Tandem  t:slim X2 with Control -
IQ Technology vs SC for 16 weeks . All participants will be provided the 
option  of using t:slim X2 with Control -IQ system in a 12 week Extension 
Phase. [Figure 1] 
 224 
Figure 1: Study Design: Participants Randomized 3:1 Control -IQ Control (CLC) vs. [ADDRESS_527548] of Care  (SC) Groups . Extension phase with partial crossover of SC group 226 
switching to use Control IQ.  227 

 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 14 OF 76 
 SCHEMATIC OF STUDY DESIGN  228 
 229 
Figure 2: Schematic of Complete Study Design  230 
  231 
Scre ening/ Enrollment Visit  
Eligibility assessment and informed consent  
HbA1c from local lab or POC device  and central lab sample  
Device download and adherence assessment for current CGM user  
 
CGM Placement/Training;  
Pump Training in Pump -Naïve Participants  
2-4 Week Run-In with  home use of study CGM  
(all participants) and study pump (MDI participants)  
and 4 weeks Pump Use (pump -naïve participants)  
Run-in Review Visit  
Reassess Eligibility  
Optimization of Insulin Pump Settings  
Randomization  
16 weeks  
 
Eligible  
To Skip  
Run-In*? 
No 
Yes 
*Current u se of  insulin pump and Dexcom G4, G5, or G6 CGM wit h readings captured on at least  
11 out of the previous 14 days  
Extension Phase for all participants using 
Control IQ  
12 weeks  
End of Study  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 15 OF 76 
  232 
Figure 3:  Schematic of Study Design (Post -Randomization)  233 
Randomization Visit  
 
Week 2 Visit  
Refresher training on devices  
Phone Contacts Weeks : 1, 4, 6, 10, 12, 14  
Clinic Visits:  Weeks 2, 8, 16  
 
Study system training and home use  
Training immediately after randomization with 
one week of closed -loop system use at home  
Primary Outcome  
 (16 weeks)  
CLC Group  
 SC Group  
One week of closed -loop system use 
at home  
One week of SC at home with study CGM 
and personal or study -provided pump  
One week of SC at home with study  CGM 
and personal or study -provided pump  
(2-4 weeks of training with provided 
pump training for pump naïve)  
Week [ADDRESS_527549]  
SC data assessment  
Control Participants  
Study system training and home use  
Extension Phase Phone Contacts: Weeks 17, 19, 21, 25  
Extension Phase Clinic Visits:  Weeks 16, 23, 28  
Primary Outcome of Extension Phase  (28 weeks)  
Experimental Participants  
Study system home use continued  
Extension Phase Phone Contacts:  Weeks 20, 24  
Extension Phase Clinic Visits:  Week  28  
 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 16 OF 76 
  234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
Table 1. Schedule of Study Visits and Procedures (Primary Study Phase)   247  Pre Pre 0 1w 2w 4w 6w 8w 10w 12w 14w 16w 
Visit (V) or Phone (P)  V V V P V P P V P P P V 
Comment  Screen/
Enroll  Run-in Rand           
Eligibility Assessment  X X X          
HbA1c (DCA Vantage or similar 
point of care device, or  local lab)  X  X         X 
HbA1c (Central lab)   X         X 
C-peptide (Central lab) and blood 
glucose assessment    X          
Pregnancy test (females of 
child -bearing potential)  X  X     X    X 
Device  Data download (s) X X X X X X X X X X X X 
Review diabetes management and 
AEs  X X X X X X X X   X 
Questionnaires as defined in  
section  8.2   X         X 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 17 OF 76 
 Experimental  Group  20w 24w 28w 
Visit (V) or Phone (P)  P P V 
Comment     
Eligibility Assessment     
HbA1c (DCA Vantage or similar point of care 
device, or  local lab)    X 
HbA1c (Central lab)    X 
C-peptide (Central lab) and blood glucose 
assessment     
Pregnancy test (females of child -bearing potential)    X 
Device  Data download (s) X X X 
Review diabetes management and AEs  X X X 
Questionnaires as defined in  section  8.2   X 
Table 2: Schedule of Visits and Procedures (Extension Phase for Experimental Group)   248 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 18 OF 76 
  249 
 250 
 251 
 252 
 253 
 254 
 255 
 256 
 257 
 258 
 259 
 260 
Table 3: Schedule of Visits and Procedures (Extension Phase for SC Group)  261 
 262 
 263 Control Group  17w 19w 21w 23w 25w 28w 
Visit (V) or Phone (P)  P P P V P V 
Comment        
Eligibility Assessment        
HbA1c (DCA Vantage or similar point of care device, or  local 
lab)      X 
HbA1c (Central lab)       X 
C-peptide (Central lab) and blood glucose assessment        
Pregnancy test (females of child -bearing potential)     X  X 
Device  Data download (s) X X X X X X 
Review diabetes management and AEs  X X X X X X 
Questionnaires as defined in  section  8.2      X 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 19 OF 76 
 Chapter 1:  Background Information  [ADDRESS_527550] -generation closed -loop 266 
control (CLC) system retaining the same control algorithm that was initially tested by [CONTACT_137348]’s DiAs 267 
system and then implemented in the inControl system  (TypeZero Technologies, Inc.) . DiAs is 268 
described in 13 IDEs (see  IDEs [ADDRESS_527551] below) and inControl is described on the [ADDRESS_527552] of IDEs mentioned below (i.e. in IDEs G160097, G160181, G150240, G140169/S010 ). For 270 
complete algorithmic and clinical background, we refer to these I DEs and to a number of scientific 271 
publications that describe glycemic control outcomes and clinical impressions from the use of 272 
these systems (see list of 25 peer -reviewed papers and scientific presentations under Bibliography). 273 
Overall, this control algor ithm has been implemented in two mobile platforms (DiAs and 274 
inControl) and has been tested in [ADDRESS_527553] this progress:  279 
1. IDE #G110095: Feasibility study of closed loop contr ol in type 1 diabetes using heart rate 280 
monitoring as an exercise marker, approved 10/08/2011;  281 
2. IDE #G120032: Early feasibility (pi[INVESTIGATOR_2268]) study of outpatient control -to-range; 3/2/2012;  282 
3. IDE #G120210: Early feasibility study 2 of outpatient control -to-range; 10 /12/2012;  283 
4. IDE #G130118: DiAs control -to-range nocturnal closed -loop camp study; 6/19/2013;  284 
5. IDE #G130121: Optimizing closed -loop control of type 1 diabetes mellitus in adolescents; 285 
6/19/2013;  286 
6. IDE# G130142:  Closed loop control in adolescents using heart ra te as exercise indicator; 287 
7/16/13;  288 
7. IDE #G130143: Early feasibility study of adaptive advisory/automated (AAA) control of 289 
type 1 diabetes; 7/19/2013;  290 
8. IDE #G140066:  Full day and night closed -loop with DiAs platform; 5/9/14.  291 
9. IDE #G140068: Unified Safety Syst em (USS) Virginia Closed Loop versus sensor 292 
augmented pump therapy overnight in type 1 diabetes; 5/14/2014;  293 
10. IDE #G140089: Outpatient control -to-range: Safety and efficacy with day -and-night in -home 294 
use; 6/6/2014;  295 
11. IDE #G140169: Unified Safety System (USS) V irginia Closed -Loop versus Sensor 296 
Augmented Pump (SAP) therapy for hypoglycemia reduction in type 1 diabetes; 10/3/2014.  297 
12. IDE #G150221: Reducing risks and improving glucose control during extended exercise in 298 
youth with T1DM: The AP Ski Camp; 11/09/2015;  299 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 20 OF 76 
 13. IDE #G150240: Project Nightlight: Efficacy and system acceptance of dinner/night vs. 24 hr 300 
closed loop control; 11/12/2015;  301 
14. IDE #G160047: Closed -loop in young children 5 -8 years old using DiAs platform; 302 
03/29/2016;  303 
15. IDE #G160097: Clinical Acceptance of the Artificial Pancreas: the International Diabetes 304 
Closed -Loop (iDCL) Trial/Research Site Training Protocol; 06/03/16.  305 
16. IDE#G160181: PROTOCOL 1 for “Clinical Acceptance of the Artificial Pancreas: The 306 
International Diabetes Closed Loop (iDCL) Trial; 09/21/16  307 
17. IDE#G170255: Protocol 3 for “Pi[INVESTIGATOR_36733] t:slim X2 with Control -IQ 308 
Technology”;11/16/17 and IDE#G170255/S001 Protocol 3 for “Training Study of t:slim X2 309 
with Control -IQ Technology”; 11/16/17  310 
18. IDE#G170267: “Real -Time Monitoring and Glucose Control During Winter -Sport Exercise 311 
in Youth with Type 1 Diabetes: The AP Ski Camp Continued”; 11/21/17  312 
19. IDE#G150240/S008: A long -term home use study, enrolling 18 -70 years old TID 313 
participants since January 2018; it is anticipated that this study will be completed April  2019.  314 
20. IDE#G170255: A p ilot study of 5 adult subjects completed  in December 2017.   315 
21. IDE#G170267 : Three 48-hour winter ski camps trial T1D participants ; one site enrolled 13- 316 
18 years old participants in January 2018. The other two sites enrolled participants aged 6 -12 317 
years old. At the conclusion of these ski camps, subjects continued  with the study device for 318 
72 hours use at home (March & April 2018 ). 319 
In the G170255 pi[INVESTIGATOR_799]  (mean age 52.8 yrs; 3F/2M, mean A1c 6.5%) , the system was 320 
challenged with a  variety of scenarios including: Pump disconnection, CGM sensor removal 321 
without stoppi[INVESTIGATOR_143523], CGM sensor change, Basal Rate change, Cartridge Change, Extended 322 
Bolus, Calibratio n at non -ideal conditions, Stoppi[INVESTIGATOR_418070] -IQ, Reset Sleep Time, Restaurant 323 
Meals and Exercise (treadmill/walk). The study demonstrated excellent connectivity with 98% 324 
time in closed -loop control and 94%-time CGM is available during 196 hours of use . [28] 325 
The results of the home portion of the IDE#G170267 /ski camp trial (Table 5) were as follow: The 326 
Control -IQ significantly improved time in target range 70 -180 mg/dL (71.0±6.6 vs. 52.8±13.5%; 327 
p=0.001) and mean sensor glucose (153.6±13.5 vs. 180.2±23.1 mg/dL ; p=0.003) without 328 
increasing hypoglycemia time <70 mg/dL (1.7 [1.3 -2.1] vs. 0.9 [0.3 -2.7]%; ns). The HCL system 329 
was active for 94.4% of the study period. Subjects reported that use of the system was associated 330 
with less time thinking about  diabetes, decreased worry about blood sugars, and decreased burden 331 
in managing diabetes.  [33] 332 
No AE or SAE happened during the se trials related to the equipment used.  333 
  334 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 21 OF 76 
 METRIC (COMPUTED DUR ING CLOSED -LOOP USE)  OVERALL  DAYTIME  NIGHTTIME  
Mean glucose (mg/dL)  129 135 121 
Coefficient of variation (median)  27% 27% 21% 
% below 54 mg/dL (median)  0.7%  0.0%  0.0%  
% below 60 mg/dL (median)  1.1%  2.0%  0.0%  
% below 70 mg/dL (median)  2.9%  4.1%  1.0%  
Percent in range 70 -180 mg/dL (mean)  87%  82%  94%  
% above 180 mg/dL (median)  5% 8% 6% 
% above 250 mg/dL (median)  0% 0% 0% 
% above 300 mg/dL (median)  0% 0% 0% 
Table 4. Pi[INVESTIGATOR_418071] -loop 335 
 336 
Table 5 . Glycemic Outcomes Measured by [CONTACT_28047]: Ski  camp and home use trial  337 
Closed -Loop Control System  338 
The Closed -Loop Control System contained in t -slim X2 with Control -IQ Technology is described 339 
in Master File MAF -2032/A008. Control -IQ Technology is derived from inControl previously 340 
described in IDE# G16 0097, G160181, G150240 and G140169/S010. The CLC is an  “artificial 341 
pancreas” (AP) application that uses advanced closed loop control algorithms to automatically 342 
manage blood glucose levels for people with Type 1 Diabetes. The system modulates insulin to 343 
keep blood glucose in a targeted range. The system components include the  t:slim X2 with 344 
Control -IQ Technology and the Dexcom CGM G6.  345  
OVERALL  DAYTIME [7AM - 11 PM]  NIGHTIME [11PM - 7AM]   
Control -
IQ SAP  p-
value  Control -IQ SAP  p-
value  Control -IQ SAP  p-
value  
70 - 180 mg/dL 
(%) 71.0 ± 6.6  52.8 ± 13.5  0.001  69.1 ± 10.1  54.4 ± 14.2  0.010  74.9 ± 10.1  49.6 ± 18.8  0.001  
< 50 mg/dL (%)  0 [0-0.1] 0 [0-0.4] ns 0 [0-0] 0 [0-0.6] ns 0 [0-0] 0 [0-0] ns 
< 54 mg/dL (%) 0.2 [0 -0.5] 0.2 [0 -0.6] ns 0 [0-0.4] 0.3 [0 -0.9] ns 0 [0-0] 0 [0-0] ns 
< 60 mg/dL (%)  0.7 [0.2 -1] 0.5 [0 -0.9] ns 0.3 [0 -1.1] 0.7 [0 -1.3] ns 0 [0-0.2] 0 [0-0] ns 
< 70 mg/dL (%)  1.7 [1.3 -
2.1] 0.9 [0.3 -2.7] ns 1.6 [0.7 -2.6] 1.4 [0.5 -3.4] ns 0.7 [0 -2.6] 0 [0-0] 0.190  
> 180 mg/dL (%)  26.7 ± 7.2  44.7 ± 13.8  0.001  28.1 ± 11.1  42 ± 14.4  0.017  23.8 ± 9.9  49.9 ± 19.3  0.001  
> 250 mg/dL (%)  7.2 ± 4.5  16.1 ± 10.3  0.015  8.3 ± 6.4  14.8 ± 11  0.097  5.2 ± 8  18.7 ± 12.9  0.007  
> 300 mg/dL (%)  2.9 ± 2.7  5.3 ± 3.9  0.102  3.5 ± 3.9  4.4 ± 4.5  ns 1.8 ± 4  7.1 ± 6.5  0.030  
Mean glucose 
(mg/dL)  153.6 ± 
13.5  180.2 ± 23.1  0.003  157 ± 20.2  175.7 ± 24.7  0.064  147.1 ± 
16.4  188.8 ± 
30.2  0.001  
Coefficient of 
Variation (%)  36.6 ± 4.9  36.5 ± 5.4  ns 35.7 ± 5.3  36.8 ± 6.1  0.185  33.4 ± 7.1 32.9 ± 6.4  ns 
Insulin use (U/day)  33.2 ± 
15.5  27.8 ± 12.3  ns 26.4 ± 12.8  22.3 ± 9.6  ns 6.8 ± 2.8  5.5 ± 3  ns 
CHO treatment (g)  15.5 ± 
16.9  35.5 ± 55.5  ns 14.7 ± 16.7  34.5 ± 55.7  ns 0.9 ± 2  1.2 ± 2.6  ns 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 22 OF 76 
  346 
Figure 4. t:slim X2 with Control -IQ and Dexcom G6 system  [ADDRESS_527554] of care. In addition, the data 350 
from this trial may be used for subsequent PMA application for this system.  351 
The 12-week  extension phase will allow for additional exposure time to the Tandem t:slim X2 with Control - 352 
IQ Technology  and evaluation of the SC arm when crossover to use Control IQ for 12-week  period.   353 
 Potential Risks and Benefits of the Investigational Device  354 
Risks a nd Benefits are detailed below. Loss of confidentiality is a potential risk; however, data are 355 
handled to minimize this risk.  Hypoglycemia, hyperglycemia and ketone formation are always a 356 
risk in participants with type 1 diabetes and participants will be monitored for these events . 357 
 
 358 
[IP_ADDRESS]  Venipuncture Risks  359 
A hollow needle/plastic tube will be placed in the arm for taking blood samples. Blood draws can 360 
cause some common reactions like pain, bruising, or redness at the sampling site.  Les s common 361 
reactions include bleeding from the sampling site, formation of a small blood clot or swelling of 362 
the vein and surrounding tissues, and fainting.  363 
[IP_ADDRESS]  Fingerstick Risks  [ADDRESS_527555] for several weeks.  The risk of local 368 
infection is less than 1 in 1000.  This should not be a significant contributor to risks in this study 369 
as fingersticks are part of the usual care for people with diabetes.  370 
[IP_ADDRESS]  Subcutaneous Catheter Risks  (CGM)  371 
Participants using the CGM will be at low risk for developi[INVESTIGATOR_007] a local skin infection at the site of 372 
the sensor needle placement.  If a catheter is left under the skin for more than 24 hours , it is possible 373 

 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 23 OF 76 
 to get an infection where it goes into the skin, with swelling, redness and pain.  There may be 374 
bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk).  [ADDRESS_527556] a s mall portion of the sensor under the skin that may cause redness, swelling or pain at the 377 
insertion site.  The participant should be further instructed to notify the study coordinator 378 
immediately if this occurs.  379 
[IP_ADDRESS]  Risk of Hypoglycemia  380 
As with any person havi ng type 1 diabetes and using insulin, there is always a risk of having a low 381 
blood sugar (hypoglycemia).  The frequency of hypoglycemia should be no more and possibly less [ADDRESS_527557] as at home, there is the possibility of fainting or seizures 384 
(convulsions) and that for a few days the participant may not be as aware of symptoms of 385 
hypoglycemia.  A CGM functioning poorly and significantly o ver-reading glucose values could 386 
lead to inappropriate insulin delivery.  387 
[IP_ADDRESS]  Risk of Hyperglycemia  388 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 389 
extended period or if the pump or infusion set is not working prope rly.  A CGM functioning poorly 390 
and significantly under -reading glucose values could lead to inappropriate suspension of insulin 391 
delivery.  392 
[IP_ADDRESS]  Risk of Device Reuse  393 
The study CGM system is labeled for single use only. The sensor (the component of the system 394 
that enters the skin) will be single use only. The receiver, if used, is a hand -held device. The [ADDRESS_527558] approved these devices 398 
for single use and that by [CONTACT_28040], bloodborne pathogens (i.e. Hepatitis 399 
B) may be spread thr ough the use of multiple users.  400 
The study insulin pump is labeled for single -patient use. During the study, this device may be 401 
reused after cleaning adhering to a hospi[INVESTIGATOR_307] -approved cleaning procedure. All infusion set 402 
equipment will be single patient use o nly (infusion set insertion kits, tubing, cartridges etc.)  403 
Participants will be informed that FDA or relevant national authorities typi[INVESTIGATOR_418072] 404 
pump device for single use and that by [CONTACT_28040], bloodborne pathogen s 405 
(i.e. Hepatitis B) may be spread through the use of multiple users.  406 
The study blood glucose meter and blood ketone meter are labeled for single -patient use. 407 
During  the study, only one person can use each device as there are rare risks that bloodborne 408 
pathogens (i.e. Hepatitis B) may be spread through the use of multiple users.  409 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 24 OF 76 
 [IP_ADDRESS]  Questionnaire  410 
As part of the study, participants (parent and child) will complete questionnaires which include [ADDRESS_527559] been unco mmon.  415 
[IP_ADDRESS]  Other Risks  416 
Some participants may develop skin irritation or allergic reactions to the adhesives used to secure 417 
the CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  418 
If these reactions occur, different adh esives or “under -tapi[INVESTIGATOR_007]” (such as with IV 3000, Tegaderm, 419 
etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_91101] 420 
medication may be required.  421 
Whenever the skin is broken there is the possibility of an infection.  Th e CGM and pump infusion 422 
sites are inserted under the skin.  It is possible that any part that is inserted under the skin may 423 
cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or 424 
topi[INVESTIGATOR_27996].   The risk of skin problems could be greater if you use a sensor for 425 
longer than it is supposed to be used.  Therefore, participants  (and parents)  will be carefully 426 
instructed about proper use of the sensor.  427 
Data downloaded from the CGM, pump, and the home  glucose and ketone meter will be collected 428 
for the study as measures of diabetes self -management behaviors.  Some people 429 
may be uncomfortable with the researchers' having such detailed information about their daily 430 
diabetes habits.  431 
 
 432 
One purpose of this research is to reduce the frequency of hypoglycemia and severe hypoglycemic 433 
events. Hypoglycemia is the number one fear of many individuals and families with someone who 434 
has type 1 diabetes and this fear often prevents optimal glycemi c control.  435 
It is expected that this protocol will yield increased knowledge about using an automated 436 
closed -loop system  to control the glucose level and is intended to develop data to support a future 437 
PMA -application. The individual participant may not ben efit from study participation.  438 
 
 439 
Based on the facts that (1) children and adolescents with diabetes experience mild hypoglycemia 440 
and hyperglycemia frequently as a consequence of the disease and its management, (2) the study 441 
intervention invol ves periodic automated insulin dosing that may reduce  the likelihood of 442 
hypoglycemia, and periodic automated attenuation of insulin delivery that may reduce  the 443 
likelihood of hyperglycemia, (3) if any, hypo and/or hyperglycemia occur, mitigations are in pl ace, [ADDRESS_527560] been tested in prior studies using the investigational device system in the home setting, 445 
that limit the likelihood of excessive insulin dosing or prolonged withdrawal of insulin, and (4) [ADDRESS_527561] their origin in the Declaration o f Helsinki, with the 453 
protocol described herein, and with the standards of Good Clinical Practice (GCP).  [ADDRESS_527562] that the closed loop 459 
system is experimental.  Ther efore, an investigational device exemption (IDE) from the U.S. Food 460 
and Drug Administration (FDA) is required to conduct the study.  461 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 26 OF 76 
 Chapter 2:  Study Enrollment and Screening  [ADDRESS_527563] 16-week  464 
phase of  this trial.  A maximum of 150 individuals may be enrolled into screening for the study in 465 
order to achieve this goal  considering an approximately  30% withdraw al and screen failure rate. 466 
For the extension phase , all 100 participants  that were randomized and completed the main study  467 
will complete the 12-week  extension  phase . The participants randomized to SC in the main study 468 
will crossover to use t:slim x2 with Control IQ. The intervention al arm in the main study  will [ADDRESS_527564] the following minimum numbers of participants 474 
complete the trial in the specified subgroups at the time of en rollment:  475 
 At least one-third  of participants with HbA1c ≥ 8.0% and one-third  of participants with HbA1c 476 
<7.9% 477 
 At least one-third  of participants in the age range 6-[ADDRESS_527565] of  participants 11-13 years 478 
old 479 
 At least 20% of  participants who are on multiple daily injections (MDI) rather than pump  480 
 At least 20% of  participants who are CGM -naïve  (defined as not using a CGM in the prior 3 481 
months ) 482 
 
 483 
Potential eligibility may be assess ed as part of a routine -care examination.  Before completing any 484 
procedures or collecting any data that are not part of usual care, written informed consent and child 485 
assent will be obtained.  486 
A parent/legal guardian (referred to subsequently as “parent”) w ill be provided with the Informed 487 
Consent Form to read and will be given the opportunity to ask questions.  Potential participants 488 
meeting the IRB’s minimum age of assent will be given a Child Assent Form to read and discuss 489 
with his/her parents and study personnel.  If the parent and child agree to participate, the Informed 490 
Consent Form and Child Assent Form  (if applicable)  will be signed.  A copy of the consent form 491 
will be provided to the participant and his/her parent and another copy will be added to t he 492 
participant’s study record.  493 
As part of the informed consent process, each participant  and/or parent/legal guardian  will be asked 494 
to sign an authorization for release of personal information.  The investigator, or his or her 495 
designee, will review the stu dy-specific information that will be collected and to whom that 496 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 27 OF 76 
 information will be disclosed.  After speaking with the participant, questions will be answered 497 
about the details regarding authorization.  498 
A participant is considered enrolled when the informed consent form  and child assent  (if 499 
applicable)  has been signed.  [ADDRESS_527566] 6 months   505 
2. Familiarity and use of a carbohydrate ratio for meal boluses.  506 
3. Age ≥  6 and ≤ 13 years  old 507 
4. Weight ≥25 kg and ≤[ADDRESS_527567] will be required for 511 
all females of child -bearing potential. Participants who  become pregnant will be discontinued 512 
from the study. Also, participants who during the study develop and express the  intention to 513 
become pregnant within the timespan of the study will be discontinued.  514 
6. Living with one or more parent/legal guardian knowledg eable about emergency procedures for [ADDRESS_527568] emergency services and study staff . 516 
7. Willingness to suspend use of any personal  closed loop system that they use at home  for the 517 
duration of the clinical trial once the study CGM i s in use  518 
8. Investigator has confidence that the participant can successfully operate all study devices and 519 
is capable of adhering to the protocol  520 
9. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already , and to use 521 
no other insulin besides lispro (Humalog) or aspart (Novolog) during the study  for participants 522 
using the t:slim X2 . This includes:  523 
o Participants randomized to Control IQ  524 
o Participants on the SC group on MDI treatment that will be provided a Tandem 525 
pump to switch to CSII  526 
o Participates that are already in CSII randomized to SC during the extension phase 527 
when transition to Control IQ  528 
10. Total daily insul in dose (TDD) at least 10 U/day  529 
11. Willingness not to start any new non -insulin glucose -lowering agent during the course of the 530 
trial (see section 2.3) 531 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 28 OF 76 
 12. Participant and parent(s)/guardian(s) willingness to participate in all training sessions as 532 
directed by [CONTACT_464].  533 
 Participa nt Exclusion Criteria  534 
Individuals meeting any of the following exclusion criteria at baseline will be excluded from study 535 
participation.  536 
1. Concurrent use of any non -insulin glucose -lowering agent other than metformin (including 537 
GLP -1 agonists, Symlin, DPP -4 inhibitors, SGLT -2 inhibitors, sulfonylureas).  538 
2. Hemophilia or any other bleeding disorder  539 
3. A condition, which in the opi[INVESTIGATOR_66678], would put the participant or 540 
study at risk  (specified on the study procedure  manual)  [ADDRESS_527569] of employment who is also directly involv ed in 545 
conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first -degree [ADDRESS_527570] physical exam (including vital signs and height and weight measurements) will be 556 
performed by [CONTACT_418089] (a physician, research physician, resident, fellow, 557 
nurse practitioner or a physician assistant).  558 
The following procedures will be performed/data collected/eligibility criteria checked and 559 
documented:  560 
 Inclusion and exclusion criteria  assessed  561 
 Demographics (date of birth, sex, race and ethnicity)  562 
 Contact [CONTACT_3031] (retained at the clinical center and not entered into study database)  563 
 Medical history  564 
 Concomitant medications  565 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 29 OF 76 
  Physical examination to include:  566 
 Weight, height  567 
 Vital signs including measurement of blood pressure and pulse  568 
 Comprehensive Metabolic Panel to assess kidney and liver functioning  569 
Blood draw for:  570 
 HbA1c level measured using the DCA  Vantage or comparable point of care device or local lab  [ADDRESS_527571] be made within two weeks prior to enrollment  574 
o Sample to be sent to a central lab  575 
 Urine or s erum pregnancy test for all women of child -bearing potential  and sexually active.  [ADDRESS_527572] approximately 1 -2 hours . 577 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 30 OF 76 
 Chapter 3:  Run-In Phase  578 
 Run-in Phase Overview  579 
This phase may begin immediately after enrollment is complete  or may be deferred for a maximum 580 
of 28 days. The purpose of this run -in phase  is to 1) assess compliance with study procedures, 2) 581 
to introduce the study CGM to study participants without current use of a CGM and 3) to introduce [ADDRESS_527573] 11 out of the previous 14 days prior to the time of enrollment can skip the run - 585 
in phase. If a participant is using a pump with a Low Glucose Susp end (LGS) feature, they will be [ADDRESS_527574] 14 days.  592 
All participants and their parent(s) will receive training on the study CGM as detailed below. This 593 
will be an unblinded use of the study CGM.  594 
Additionally, MDI and study pump naïve participants will  participate in a pump run -in phase  that 595 
will run 2 to 6  weeks before randomization is assigned. If both pump run -in phase and CGM run - 596 
in phase are indicated, they will run concurrently. Training is detailed below.  597 
 598 
 Initiation of CGM  599 
The participant will be provided with sensors and instru cted to use the study CGM on a daily basis. 600 
Training will be provided to participants not experienced with CGM use as to how to use the CGM 601 
in real -time to make management decisions and how to review the data after an upload for 602 
retrospective review. Parti cipants using a personal CGM prior to the study will discontinue the 603 
personal CGM beginning in this period.  604 
The participant will be observed placing the sensor. The study CGM user’s guide will be provided 605 
for the participant to take home.  606 
 Initiation of Pump  607 
Pump-naïve participants will use the study insulin pump and CGM for up to 4 weeks before 608 
randomization is assigned.  609 
Participants who are pump -naïve will be provided with a study pump similar to the pump used 610 
with the closed -loop system, but with the closed -loop control feature either absent or deactivated  611 
and will be instructed to use the pump on a daily basis. An initial basal insulin profile will be 612 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 31 OF 76 
 customized on a per -participant basis. Total daily insulin dose will be reduced by [CONTACT_3450] 613 
20% as a general rule, with a recommended method outlined in a separate procedures’  manual. 614 
Further adjustments to total daily dose  (TDD)  and intraday basal rate profile may be made during 615 
the course of the run -in period  that can be concomitant with the CGM run -in phase.  616 
Participants and parent(s) will complete training on the study pump as detailed below.  617 
 The participant will be fully instructed on the study insulin pump. A qualified system trainer [ADDRESS_527575]  (IOB)  and correction boluses.  620 
 The study pump will have the Basal -IQ feature, and participants will be able to use this feature  621 
at investigator discretion . 622 
Additional topi[INVESTIGATOR_418073]: infusion site initiation, cartridge/priming 623 
procedures, setting up the pump, charging the pump, navigation through  menus, bolus 624 
procedures including stoppi[INVESTIGATOR_007] a bolus, etc.  625 
 For pu mp-naïve participants, t he study team will assist the participant in study pump infusion 626 
site initiation and will start the participant on the study pump . The study pump will be 627 
programmed with the participant’s insulin requirements .  628 
 The participant will be supervised with the study pump during at least one meal or snack bolus 629 
to ensure participant understanding of the pump features.   630 
 The participant will be encouraged to review the literature provided with the pump and infusion 631 
sets after the training is completed.  632 
 633 
Note: For the extension  phase , participant s in the control group will be trained on the use of the 634 
Control IQ system.  Follow up phone contacts and in -clinic visits are described  in Table 3. 635 
 636 
 Blood Glucose and Ketone Testing  637 
Participants will receive supplies for blood glucose and ketone testing.  638 
 Blood glucose testing  [ADDRESS_527576] 640 
control solution to perform quality control (QC) testing at home per manufacturer guidelines.  [ADDRESS_527577] strips, and control solution if a meter 645 
fails QC testing at home.  646 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 32 OF 76 
 o Participants will be reminded to use the study blood glucose meter for all fingerstick BGs 647 
during the study.  648 
o Participants will be given guidelines for treatment of low or high blood glucose.  649 
 Blood ketone testing  [ADDRESS_527578] strips, and control solutio n if a meter 656 
fails QC testing at home.   657 
o Participants will be instructed to perform blood ketone testing as described in section  7.1.6 . 658 
o Participants will be given guidelines for treatment of elevated blood ketones  659 
 Participants will be required to have a ho me glucagon emergency kit. Participants who [ADDRESS_527579] the participant with any system use issues. Visit procedures 665 
will include the following:  666 
 Asse ssment of compliance with the use of either or both  CGM and /or study pump (if 667 
applicable)  668 
 Assessment of compliance with the use of:  669 
o CGM,  670 
o study pump,  671 
o CGM and study pump  672 
 Assessment of skin reaction in areas where a CGM sensor was worn  673 
 Assessment of eligi bility to continue to the randomized control trial  (RCT )  phase of the study  [ADDRESS_527580] 2 weeks of the 675 
run-in phase ha ve been completed ; participants will be evaluated for compliance and progress. If [ADDRESS_527581] 11 out of the previous 14 days  of the run -in phase  (if applicable)  and pump - [ADDRESS_527582] successfully used the study pump each day  (if applicable) .  If a participant [ADDRESS_527583] to ensure competency.   695 
Participants who are unable to meet the CGM or study pump compliance requirements and those 696 
who no longer meet all of the inclusion and exclusion criteria will be withdrawn from the study.  697 
If the participant is eligible to continue in the study, study staff will follow the procedure for insu lin 698 
pump optimization described below in section  3.6. 699 
 Optimization of Insulin Pump Settings  700 
 Data -driven optimization of pump settings will occur at the following times:  701 
 For the first phase:  Prior to Randomization:  702 
o At the Run -in Review Visit  703 
 Following Randomization  visit and initiation of Extension Phase : 704 
o If needed at the criteria of the physician at each clinical center , optimization may be done 705 
by [CONTACT_418090] o r in clinic visits.  706 
o If the study participant contacts the study physician due to concerns about their pump 707 
settings due to recurring hypo - or hyperglycemia.  708 
Data will be obtained from CGM and/or pump downloads at the visit. Adjustments to pump 709 
settings (ba sal rates, correction factor, insulin -to-carbohydrate ratio, etc.) will be made in response 710 
to major trends observed in the CGM data, with flexibility for clinicians to adhere to guidelines 711 
and practices established at each individual practice rather than a fixed set of heuristics for all 712 
clinical centers . 713 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 34 OF 76 
 Chapter 4:  Randomization Visit  714 
 Randomization Visit  715 
The visit may occur on the same day as the Screening or Run-in Review Visit , or on a subsequent 716 
day. If deferred, the randomization visit should occur  no more than 14 days after screening (if Run - 717 
in skipped) or successful completion of the run -in phase.  [ADDRESS_527584] will be repeated for all females of child -bearing potential  if this visit is not 719 
on the same day as the Screening Visit . 720 
 
 721 
HbA1c will be measured using DCA Vantage or similar point -of-care ( POC ) device or local lab  if 722 
this visit is not on the same day as the Screening Visit .  A blood sample also will be drawn to send 723 
to the central laboratory for baseline HbA1c determination to be used in outcome analyses.  724 
 
 725 
A blood sample will be drawn to send to the central laboratory for a random, non -fasting C -peptide 726 
determination to characterize baseline residual insulin production.  In conjunction, blood gluco se 727 
may be measured using a blood glucose meter or a blood sample may be drawn to send to the 728 
central laboratory for a blood glucose assessment.  729 
 
 730 
Eligible participants will be randomly assigned to one of two treatment groups in a 3:1 ratio:  731 
1. Control-IQ Closed -Loop Control ( CLC ) Group  [ADDRESS_527585] of Care (SC) Group  733 
The participant’s randomization group assignment is determined by [CONTACT_12550] a Randomization [ADDRESS_527586] not randomize a 738 
participant until he/she is  convinced that the participant/parent will accept assignment to either [ADDRESS_527587] for in analysis than will clinical center  in view of the relatively small number at each clinical 743 
center . 744 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 35 OF 76 
 
 
 745 
Participants will complete a set of baseline questionnaires, described in section 8.2 adapted for 746 
age, prior to randomization.   747 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 36 OF 76 
 Chapter 5:  Main Study Procedures   748 
 Procedures for the CLC Group  749 
Participants assigned to the CLC group will receive study system training. These training 750 
sessions can occur on the same day or extend to up to one additional day if needed within 1 -7 751 
days from randomization; participants will not take the study system home until training has 752 
been completed.  753 
The parent/guardian will be trained on severe hypoglycemia emergency procedures including 754 
removal of the study pump and administration of glucagon. The  parent/guardian will be asked to 755 
attend any/all of the other training procedures.   756 
 Study System Training  757 
Participants will receive study system training by a qualified trainer. The study system includes 758 
the Tandem t:slim X2 with Control -IQ technology and associated Dexcom G6 CGM.  759 
CGM training will include:  760 
 The participant will be instructed and supervised on how to insert the sensor a nd transmitter.  761 
 The participant will learn how to calibrate the CGM unit  762 
 The participant will learn how to access the CGM trace via the t:slim X2 with Control -IQ user 763 
interface  764 
 Participants will be asked to perform fingerstick blood glucose measurements in  accordance 765 
with the labeling of the study CGM device  766 
Pump training will include:  767 
 The participant will be fully instructed on the study insulin pump. A qualified system trainer [ADDRESS_527588] and correction boluses. Additional 770 
topi[INVESTIGATOR_137345]: infusion site initiation, cartridge/priming procedures, 771 
setting up the pump, charging the pump, navigation through menus, bolus procedures including 772 
stoppi[INVESTIGATOR_007] a bolus, etc.  773 
 The study team will assist the participant in study pump infusion site initiation and will start 774 
the participant on the study pump. The study pump will be programmed with the participant’s 775 
usual basa l rates and pump parameters. The participant’s personal pump will be removed.  776 
 The participant will be supervised with the study pump during at least one meal or snack bolus 777 
to ensure participant understanding of the pump features.  778 
 The participant will be e ncouraged to review the literature provided with the pump and infusion 779 
sets after the training is completed.  780 
Pump training specific to the Control -IQ Technology functions will include:  781 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 37 OF 76 
  How to turn on and off Control -IQ technology.  782 
 How to understand when Co ntrol -IQ is increasing or decreasing basal rates.  783 
 How to administer a meal or correction bolus on the t:slim X2 with Control -IQ system  784 
 What to do when exercising while using the system  785 
 How to enable the sleep function and set the sleep schedule  786 
 The participant will be assessed for understanding of the system interface and how to react to 787 
safety/alert messages.  788 
 The participant will be given a User Guide as a reference.  789 
 
 790 
The participant will be instructed to use the system in closed -loop mode except 1) when no 791 
calibrated CGM sensor is available or 2) if insulin is delivered by [CONTACT_418091] 792 
study  pump (e.g. injection of subcutaneous insulin via syringe in the event of infusion site failure). [ADDRESS_527589] study staff during periods of illness with an 796 
elevated temperature >101.5 degrees Fahrenh eit (38.6 degrees Celsius), periods of significant 797 
illness, or during periods of use of medications such as epi[INVESTIGATOR_418074] 798 
of a severe allergic reaction or asthma attack in addition to use of oral or injectable glucocorticoids 799 
to determine if closed -loop use should be temporarily discontinued.  800 
The participant’s parent/legal guardian will be required to attend the training procedures  and will [ADDRESS_527590] information and will be asked to call the study 805 
clinical  staff for any health -related  issues and for technical issues with t:slim X2 with [ADDRESS_527591] is required and will make 810 
arrangements with the participant for the contacts.  If the parti cipant cannot be reached, the 811 
participant’s other contact [CONTACT_367230], including the emergency contact.  Participants 812 
who are not compliant with the arranged contacts on two separate occasions may be  discontinued 813 
at the discretion of the inves tigator.  814 
Upon completion of the t:slim X2 with Control -IQ training, study staff will document, using a [ADDRESS_527592], that the participant is familiar with the function/feature and/or capable of performing 816 
each of the tasks specified.  817 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 38 OF 76 
 Participants will be pro vided Hypoglycemia, Hyperglycemia and Ketone Guidelines ( section 7.2) 818 
for when their glucose levels are >300 mg/dL for more than two hours or >400 m g/dL at any time 819 
or <70 mg/dL or ketones ≥1.5 mmol/L.  820 
 
 821 
After training on the study system has been completed, participants will proceed with home use 822 
(meaning free -living use at school , home, etc.) of the t:slim X2 with Control -IQ technology [ADDRESS_527593] 829 
every 3-week  basis throughout the remainder of the study.  830 
 
 831 
Study staff will perform a phone call with the participant with in 7 (±1) days  following 832 
randomization.  833 
The following will occur:  834 
 Assessment of compliance with study device use by [CONTACT_66706]  835 
 Assessment of adverse events, adverse device effects, and device issues  836 
 Study staff will answer any questions related to device use  837 
Participants will then complete an additional week of home use with the study system.  Participants 838 
will return to clinic 14 (±3) days from the date of randomization.  839 
 
 840 
The participant will be offered review training to address any questions on the use of the study 841 
device including meal bolus strategies and strategies related to pump use and exercise.  842 
The following will occur:  843 
 Assessment of compliance with s tudy device use by [CONTACT_66706]  844 
 Assessment of adverse events, adverse device effects, and device issues  845 
 Study staff will answer any questions related to de vice use and follow the procedure for insulin 846 
pump optimization described in s ection 3.6 using the study CGM available data from the 847 
previous two weeks.  848 
 The blood glucose meter and study ketone meter will be downloaded and QC tested with 849 
control solution.  850 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 39 OF 76 
 
 Procedures for the S C Group  851 
Participants in the S C group will use an insulin pump that they usually use for the treatment of 852 
their diabetes or a study pump provided by [CONTACT_418092] 853 
pump for the study, in conjunction with the study CGM, study blood glucose meter, and study 854 
ketone meter. Study pump training and/or study CGM training will be provided if the participant 855 
is initiating use of these devices at this point.  856 
If a participant is using a pump with a LGS feature, he/she will be allowed to continue using this [ADDRESS_527594] and prior to the 2 -week clinic visit for clinician review.  864 
Participants will be provided with any software and hardware needed to perform these data 865 
uploads.  866 
 
 867 
Study staff will perform a phone call with the participant 7(+1) days  following randomization.  868 
The following will  occur:  869 
 Assessment of compliance with study device use by [CONTACT_66706]  870 
 Assessment of adverse events, adverse device effects, and device issues  871 
 Study staff will answer any questions related to device use  872 
The participant will continue on SC for a second week, then return to the clinic 14 (±3) days from 873 
the date of randomization.  874 
 
 875 
The participant will be offered review training on the use of S C during the remainder of the study, 876 
including meal bolus strategies and strategies related to pump use and exercise.  877 
The following will occur:  878 
 Assessment of compliance with study device use by [CONTACT_66706]  879 
 Assessment of adverse events, adverse device effects, and device issues  880 
 Study staff will review uploaded CGM data, answer any questions related to device use, and 881 
follow the procedure for insulin pump optimization described in section 3.6. 882 
 The study blood glucose meter and study ketone meter will be downloaded and QC tested with [ADDRESS_527595] is required and will make 889 
arrangements with the participant for the contacts.  If the participant or parent/guardian, cannot be 890 
reached, the participant’s other contact [CONTACT_418093], including the emergency contact.  891 
 
 892 
Follow -up visits in clinic will occur at:  893 
 2 week ( ±3 days) 894 
 8 weeks ( ±1 week)  895 
 16 weeks (+1 week) – end of Main Study Phase  896 
[IP_ADDRESS]  Procedures at Follow -up Visits  897 
Procedures performed in both groups at each vi sit, unless otherwise specified below:  898 
 Assessment of compliance with study device use by [CONTACT_66706]  899 
 Assessment of adverse events, adverse device effects, and device issues  900 
 Download of device data (study system or personal pump and study CGM, study BG meter, 901 
study ketone meter)  [ADDRESS_527596] described above for the respective treatment groups, the 904 
following phone contacts will be made:  905 
 4 weeks ( ±3 days)  906 
 6 weeks ( ±3 days)  907 
 10 weeks ( ±3 days)  908 
 12 weeks ( ±3 days)  909 
 14 weeks ( ±3 days)  [ADDRESS_527597] , the following procedures are performed in both treatment groups:  911 
 Review of available CGM and/or system data to identify any safety issues associated with 912 
insulin pump settings and current diabetes m anagement approach  913 
 Assessment of adverse events, adverse device effects, and device issues  [ADDRESS_527598] once every 4 weeks  during the 917 
extension phase. The study staff will confirm that the data were received.  918 
 
 919 
All participants will return to the clinic for a 16-Week (+7 days) final clinic visit during which the 920 
following will occur:  921 
 HbA1c determi nation using the DCA Vantage or similar point of care device  922 
 Collection of a blood sample to send to the central laboratory for HbA1c determination  923 
 Completion of questionnaires  924 
 Weight and height measurement will be repeate d 925 
 Assessment of adverse events, a dverse device effects, and device issues  926 
 Download of device data (study system or personal pump and study CGM, study BG meter, 927 
study ketone meter)  928 
 Early Termination Visit (If Applicable)  [ADDRESS_527599] unscheduled visits during the study period if required for additional device 933 
training or other unanticipated needs per the study investigator discretion.  934 
 Participant Access t o Study Device at Study Closure  935 
Participant will return all investigational study devices and supplies (insulin pump, CGM and 936 
related supplies) at study closure.  Participant may keep the study ketone meter and study 937 
glucometer if these devices are not marked for investigational use only.    938 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 42 OF 76 
 Chapter 6:  Extension Phase  Procedures    [ADDRESS_527600] completed  the 16-week  Main Study Phase will be provided the option to 943 
continue the use the t:slim with Control -IQ System for an additional 12 weeks.   944 
The following phone contacts will be made for CLC Group participants in the Extension Phase:  945 
 20 week  (±3 days)   946 
 24 week  (±3 days)   [ADDRESS_527601], the following procedures are performed:  948 
Review of available CGM and/or system data to identify any safety issues associated with insulin 949 
pump settings and current diabetes management approach  950 
 Assessment of advers e events, adverse device effects, and device issues  951 
 SC Group P articipants  952 
Training on pump (section 5.2) use will be provided and therapy optimizat ion will occur as 953 
follows:  954 
 If needed at the criteria of the physician at each clinical center , optimization may be done at 955 
either phone contacts or in clinic visits.  956 
 If the study participant contacts the study physician due to concerns about their pump se ttings 957 
due to recurring hypo - or hyperglycemia.  958 
Data will be obtained from CGM and/or pump downloads at the visit. Adjustments to pump 959 
settings (basal rates, correction factor, insulin -to-carbohydrate ratio, etc.) will be made in response 960 
to major trends o bserved in the CGM data, with flexibility for clinicians to adhere to guidelines 961 
and practices established at each individual practice rather than a fixed set of characteristics  for all 962 
clinical centers . 963 
The following phone contacts will be made for SC Group participants in the Extension Phase:  964 
 17 week s (±3 days)   965 
 19 weeks  (±3 days)   966 
 21 weeks  (±3 days)   967 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 43 OF 76 
  25 weeks (±3 days)   [ADDRESS_527602], the following procedures are performed:  969 
 Review of available CGM and/or system data to identify any safety  issues associated with 970 
insulin pump settings and current diabetes management approach  971 
 Assessment of adverse events, adverse device effects, and device issues  972 
Follow -up visits for SC group during the Extension Phase in clinic will occur at:  973 
 23 Week s (±1 week)  974 
 28 Week s (+1 week) – End of Study  975 
Procedures Specific to the 28 Week Visit  976 
 HbA1c determination using the DCA Vantage or similar point of care device  977 
 Collection of a blood sample to send to the central laboratory for HbA1c determination  978 
 Completion of  questionnaires  979 
 Weight measurement will be repeated, in addition to height  980 
 Insulin Pump Optimization as described above  981 
 Early Termination Visit (If Applicable)  [ADDRESS_527603] unscheduled visits during the study period if required for additional device 986 
training or other unanticipated needs per the study investigator discretion.  987 
 Participant Access to Study Device at Study Cl osure  988 
Participant will return all investigational study devices and supplies (insulin pump, CGM and 989 
related supplies) at study closure.  Participant may keep the study ketone meter and study 990 
glucometer if these devices are not marked for investigational us e only.  991 
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 44 OF 76 
 Chapter 7:  Study Devices  992 
 Description of the Investigational Device  993 
 
 994 
The study system will include the Tandem t:slim X2 with Control -IQ technology.  995 
 
 996 
The study CGM will include Dexcom G6 transmitter and sen sors when using the Tandem t:slim [ADDRESS_527604] once every 10 days.  1000  
 
 1001  
Blood glucose levels will be measured using the study ’s blood glucose meter (glucometer) and the 1002  
CGM device will be calibrated if needed using the study  glucometer and  strips in accordance with 1003  
the manufacturer’s labeling.  1004  
 
 1005  
Blood ketone levels will be measured using the Abbott Precision Xtra meter and strips in 1006  
accordance with the manufacturer’s labeling.  The blood glucose meter component of the Precision 1007  
Xtra device will not be used.  1008  
 
 1009  
Device accountability procedures will be detailed in the clinical center  procedures manual.  1010  
 
 1011  
 Participants to perform QC testing at home per manufacturer guidelines.  1012  
 All study blood ketone meters will be QC tested with control solution if available during all [ADDRESS_527605] strips, and control solution if a meter 1016  
fails QC testing at home.  1017  
 Participants will be instructed on how to perform blood ketone testing.  1018  
 Participants will be given guidelines for treatment of elevated blood ketones.  [ADDRESS_527606] insulin. If the CGM is not connected, the 1026  
system will revert to usual function of the pump and deliver insulin with the insulin dosing 1027  
parameters programmed in the system for that individual. Resum ption of Closed -Loop will 1028  
occur  automatically once CGM signal is available again.  1029  
If the study system is unable to activate Control -IQ for any reason, the pump will automatically 1030  
revert to preprogrammed basal insulin delivery without any need for instructi on from the user.  1031  
If the t:slim X2 detects a system error that does not allow the pump to operate, the Malfunction [ADDRESS_527607] Tandem Technical Support via 1033  
the study team.  1034  
 
 1035  
During the course of the study, participants will be permitted to change the CGM low glucose 1036  
threshold alert setting  on their device or mobile app , but will be instructed to choose a value no 1037  
less than 70 mg/dL.  1038  
The t:slim X2 with Con trol-IQ system will issue a  predictive  hypoglycemia alert (Control -IQ Low 1039  
Alert) when the system predicts BG <70 mg/dL within the next 15  minutes (<80 mg/dL when 1040  
exercise mode is activated ). 1041  
If the participant receives a Control -IQ Low Alert , a message app ears on the user interface ( UI) 1042  
that is accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_941] [ADDRESS_527608] blood sugar an d treat with carbs.  1045  
 
 1046  
During the course of the study, participants will be permitted to change the CGM high glucose 1047  
threshold alert setting  on their device or mobile app , but will be instructed to choose a value no 1048  
greater than 300 mg/dL.  1049  
The t:slim X2 with Control -IQ system will issue a predictive hyperglycemia alert (Control -IQ 1050  
High Alert) when the system has increased insulin delivery, but detects a CGM value above 200 1051  
mg/dL and does not predict the value  will decrease in the next 30 minutes.  1052  
If the participant receives a Control -IQ High Alert , a message appears on the UI that is 1053  
accompanied by [CONTACT_66703]/or sound if not acknowledged by [CONTACT_30799] [ADDRESS_527609] blood glucose.  1056  
If a participant’s CGM reading is >300 mg/dL for over 2 hours or ≥400 mg/dL at any point, the 1057  
participant will be instructed to take th e following steps:  1058  
 Perform a blood glucose meter check.  1059  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 46 OF 76 
  If the blood glucose is >300 mg/dL, check for blood ketones with the study ketone meter.  1060  
 If the ketone level is ≥1.5  mmol/L, take correction insulin, change insulin (pump) infusion site [ADDRESS_527610] udy staff.  1062  
 If a participant administers correction insulin via insulin syringe, participants will be instructed 1063  
to turn Control -IQ off for approximately four hours.  1064  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 47 OF 76 
 Chapter 8:  Testing Procedures and Questionnaires  1065  
 Laboratory Testing  1066  
 
 1067  
A blood sample will be obtained at screening to assess kidney and liver functioning.  1068  
 
 1069  
 Performed locally at the Screening visit , Randomization visit and the 16 -week  visit.  1070  
 A blood sample will be obtained and sent to central lab  at the Randomization visit , at the 16 - 1071  
week visit  and at the end of the study visit .  1072  
 
 1073  
Performed locally for females of child -bearing potential at the Screening visit and the  1074  
Randomization visit . This will also be done anytime pregnancy is suspected.  1075  
 
 1076  
Blood samples will be obtained and sent to the central lab at the Randomization visit. Back -up 1077  
samples will be stored on -site until all samples are resulted.  1078  
 Questionnaires  1079  
Questionnaires are completed at the Randomization Visit and Week 16 Visit  for all participants.  1080  
Participants who complete the Extension Phase will also complete the questionnaires at Week 28 . 1081  
The questionnaires  will be family and age appropriate  are described briefly below.  The procedures 1082  
for administration are described in the clinical center procedures manual.  1083  
The following questionnaires will be completed at the Randomization Visit : 1084  
 Clarke’s Hypoglycemia Awareness Scale  – Child and Parent ( Children age 10+ years at the 1085  
time of consent will complete as well as all Parents)  1086  
 Fear of Hypoglycemia Survey (HFS -II) – Child and Parent  1087  
 Problem Areas In Diabetes Survey (PAID) – Child and Parent  1088  
 Pediatric Quality of Life – Child and Parent   1089  
 INSPI[INVESTIGATOR_418075] y – Child and Parent  1090  
 Pi[INVESTIGATOR_2272] (PSQI) – Parent  1091  
The following questionnaires will be completed at the Week 16 and Week 28 Visit s: 1092  
 Clarke’s Hypoglycemia Awareness Scale  – Child and Parent (Children age 10+ years at the 1093  
time of consent wi ll complete as well as all Parents)  1094  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 48 OF 76 
  Fear of Hypoglycemia Survey (HFS -II) – Child and Parent  1095  
 Problem Areas In Diabetes Survey (PAID) – Child and Parent  1096  
 Pediatric Quality of Life – Child and Parent  1097  
 INSPI[INVESTIGATOR_418076]-Assessment Survey  – Child and Parent  1098  
 Pi[INVESTIGATOR_2272] (PSQI) – Parent   1099  
 System Usability Scale (SUS) – Closed -Loop participants only  1100  
Administration time is approximately 15 minutes.  1101  
 
 1102  
The scale comprises eight questions characterizing the participant's exposure to epi[INVESTIGATOR_1841] 1103  
of moderate and severe hypoglycemia. It also examines the glycemic threshold for, and 1104  
symptomatic responses to hypoglycemia. A score of four or more on a scale of 0 t o 7 implies 1105  
impaired awareness of hypoglycemia.  1106  
Administration time is approximately 5 minutes.  1107  
 
 1108  
The Hypoglycemia Fear Survey -II was developed to measure behaviors and worries rela ted to fear 1109  
of hypoglycemia in adults with type 1 diabetes. It is composed of 2 subscales, the Behavior (HFS - 1110  
B) and Worry (HFS -W). HFS -B items describe behaviors in which patients may engage to avoid 1111  
hypoglycemic epi[INVESTIGATOR_49591]/or their negative consequences  (e.g., keepi[INVESTIGATOR_418077] 1112  
higher , making sure other people are around, and limiting exercise or physical activity). HFS -W [ADDRESS_527611] about their hypoglycemic epi[INVESTIGATOR_1841] (e.g., 1114  
being alone, epi[INVESTIGATOR_418078], or having an accident).  HFS-II was adapted for 1115  
children and parents.  Items are rated on a 5 -point Likert scale (0=never, 4=always), with higher 1116  
scores indicating higher fear of hypoglycemia.  1117  
Administrati on time is approximately 10 minu tes (both versions) . 1118  
 
 1119  
The Problem Areas In Diabetes Survey is a measure of diabetes -related emotional distress and 1120  
consists of a scale of 16 items  for the Parent version and 11 items for the Child v ersion . Patients 1121  
and parents rate the degree to which each item is currently problematic for them on a 6 -point Likert 1122  
scale, from 1 (no problem) to 6 (serious problem).  [ADDRESS_527612] been validated for child self -report (5 -7 year old; 8 -12 year old; and 1127  
12-18 year old) and parent report for these same age gr oups. Participants record the extent to 1128  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 49 OF 76 
 which they (or their child) experienced each of 33 problems related to diabetes in the prior 1129  
month.   1130  
Administration time is approximately 15 minutes.  1131  
 
 1132  
The INSPI[INVESTIGATOR_21392] ( Insulin Delivery Systems: Perceptions, Ideas, Reflections and Expectations) survey 1133  
was developed to assess various aspects of a user’s experience regarding automated insulin 1134  
delivery for both patients and family members. The surveys include various topi[INVESTIGATOR_418079] 1135  
patie nts with type 1 diabetes and their family members based upon >[ADDRESS_527613] -assessment contains 21 items. Response options for all surveys include a 5 -point 1139  
Likert scale from strongly agree to strongly disagree, along with an N/A option.  1140  
Administration time is approximately 5 minutes.  1141  
 
 1142  
Pi[INVESTIGATOR_2272] (PSQI)  is a 10-item questionnaire that measures the  sleep quality 1143  
and pattern of sleep in adults. S even component scores are derived, each scored 0 (no difficulty) 1144  
to 3 (severe difficul ty). The component scores are summed to produce a global score (range 0 to 1145  
21). Higher scores indicate worse sleep quality.  1146  
Administration time is approximately 5 minutes.  1147  
 
 1148  
The System Usability Sc ale (SUS) is a 10 -item questionnaire that measures the overall usability  of 1149  
a system. It is a valid and reliable measure of the perceived usability of a system and  is technology - 1150  
agnostic. The questionnaire presents statements with five response options (an choring the options 1151  
from strongly disagree to strongly agree) and asks users to rate their agreement to the statements.  1152  
User scores are transformed into a composite score, from 0 to 100, and this score is taken as an 1153  
overall measure of the system’s usabil ity; higher scores indicate better perceived usability.  1154  
Administration time is approximately 5 minutes.   1155  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 50 OF 76 
 Chapter 9:  Adverse Events, Device Issues, and Stoppi[INVESTIGATOR_1869]  1156  
 Adverse Events  1157  
 
 1158  
Adverse Event (AE):  Any untoward medical occurrence in a study participant, irrespective of the 1159  
relationship between the adverse event and the device(s) under investigation (see section 9.1.2  for 1160  
reportable adverse events for this protocol).  1161  
Serious Adverse Event (SAE):  Any untoward medical occurrence that:  1162  
 Results in death.  1163  
 Is life -threatening; (a non -life-threatening event which, had it been more severe, might have 1164  
become life -threat ening, is not necessarily considered a serious adverse event).  1165  
 Requires inpatient hospi[INVESTIGATOR_1081].  1166  
 Results in persistent or significant disability/incapacity or substantial disruption of the ability [ADDRESS_527614] no rmal life functions (sight threatening).  1168  
 Is a congenital anomaly or birth defect.  1169  
 Is considered a significant medical event by [CONTACT_13656] (e.g., 1170  
may jeopardize the participant or may require medical/surgical intervention to prevent one of 1171  
the outcomes listed above).  [ADDRESS_527615] (UADE):  Any serious adverse effect on health or safety or [ADDRESS_527616], 1174  
problem, or death was no t previously identified in nature, severity, or degree of incidence in the 1175  
investigational plan or application (including a supplementary plan or application), or any other 1176  
unanticipated serious problem associated with a device that relates to the rights, safety, or welfare 1177  
of participants (21 CFR 812.3(s)).  [ADDRESS_527617] (ADE):  Any untoward medical occurrence in a study participant which the [ADDRESS_527618] contributed (Note that an Adverse Event 1180  
Form is to be completed in addition to a Device Deficiency or Issue Form).  1181  
Device Complaints an d Malfunctions:  A device complication or complaint is something that 1182  
happens to a device or related to device performance, whereas an adverse event happens to a 1183  
participant.  A device complaint may occur independently from an AE, or along with an AE.  1184  
An AE may occur without a device complaint or there may be an AE related to a device complaint.  1185  
A device malfunction is any failure of a device to meet its performance specifications or otherwise 1186  
perform as intended.  Performance specifications include all cl aims made in the labeling for the 1187  
device.  The intended performance of a device refers to the intended use for which the device is 1188  
labeled or marketed. (21 CFR 803.3).  Note: for reporting purposes, clinical centers  will not be [ADDRESS_527619] medical occurrence that meets 1192  
one of the following criteria:  [ADDRESS_527620] as defined in s ection 9.1.1 , unless excluded from reporting in section 1195  
9.2 1196  
3. An Adverse Event occurring in association with a study procedure  1197  
4. Hypoglycemia meeting the definition of severe hypoglycemia as defined below  1198  
5. Diabetic ketoacidosis (DKA) as defined below or in the absence of DKA, a hyperglycemic or [ADDRESS_527621].  Skin reactions from sensor placement are 1202  
only reportable if severe and/or required treatmen t. 1203  
Pregnancy occurring during the study will be recorded.  1204  
[IP_ADDRESS]  Hypoglycemic Events  [ADDRESS_527622] is only reportable as an adverse event 1206  
when the following definition for severe hypoglycemia is met:  the event required  assistance of 1207  
another person due to altered consciousness, and required anoth er person to actively administer 1208  
carbohydrate, glucagon, or other resuscitative actions.  This means that the participant was 1209  
impaired cognitively to the point that he/she was un able to treat himself/herself, was unable to 1210  
verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure or 1211  
coma.  These epi[INVESTIGATOR_418080] 1212  
coma.  If plasma gl ucose measurements are not available during such an event, neurological 1213  
recovery attributable to the restoration of plasma glucose to normal is considered sufficient 1214  
evidence that the event was induced by a low plasma glucose concentration.  1215  
[IP_ADDRESS]  Hyperglycemic E vents/Diabetic Ketoacidosis  [ADDRESS_527623] is only reportable as an adverse 1217  
event when one of the following 4 criteria is met:  1218  
 the event involved DKA, as defined by [CONTACT_3467] ( DCCT) 1219  
and described below  1220  
 evaluation or treatment was obtained at a health care provider facility for an acute event 1221  
involving hyperglycemia or ketosis  1222  
 blood ketone level ≥1.5  mmol/L and communication occurred with a health care provider at 1223  
the time of the  event  1224  
 blood ketone level ≥3.0 mmol/L, even if there was no communication with a health care 1225  
provider  1226  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 52 OF 76 
 Hyperglycemic events are classified as DKA if the following are present:  1227  
 Symptoms such as polyuria, polydipsia, nausea, or vomiting;  1228  
 Serum ketones ≥ 1.5 mmol/L or large/moderate urine ketones;  1229  
 Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and  1230  
 Treatment provided in a health care facility  1231  
All reportable Adverse Events —whether volunteered by [CONTACT_2299], discovered by [CONTACT_3449] [ADDRESS_527624], or other 1233  
means —will be reported on an adverse event form online.  Each adverse event form is reviewed [ADDRESS_527625] been caused by 1238  
the study device.  1239  
To ensure consistency of adverse event causality assessments, investigators should apply the 1240  
following general guideline when determining whether an adverse event is related:  1241  
Yes 1242  
There is a plausible temporal relationship between the o nset of the adverse event and the study 1243  
intervention, and the adverse event cannot be readily explained by [CONTACT_2299]’s clinical state, 1244  
intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the adverse event follows a known pattern of 1245  
response to the  study intervention; and/or the adverse event abates or resolves upon discontinuation 1246  
of the study intervention or dose reduction and, if applicable, reappears upon re -challenge.  1247  
No 1248  
Evidence exists that the adverse event has an etiology other than the stud y intervention (e.g., 1249  
preexisting medical condition, underlying disease, intercurrent illness, or concomitant 1250  
medication); and/or the adverse event has no plausible temporal relationship to study intervention.  1251  
 
 1252  
The intensity of an  adverse event will be rated on a three point scale: (1) mild, (2) moderate, or (3) 1253  
severe.  It is emphasized that the term severe is a measure of intensity: thus , a severe adverse event 1254  
is not necessarily serious.  For example, itching for several days ma y be rated as severe, but may 1255  
not be clinically serious.  1256  
 MILD: Usually transient, requires no special treatment, and does not interfere with the 1257  
participant’s daily activities.  1258  
 MODERATE: Usually causes a low level of inconvenience or concern to the partici pant and 1259  
may interfere with daily activities, but is usually ameliorated by [CONTACT_14212].  1260  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 53 OF 76 
  SEVERE: Interrupts a participant’s usual daily activities and generally requires systemic drug 1261  
therapy or other treatment.  1262  
 
 1263  
Adverse events will be coded using the MedDRA dictionary.  The Medical Monitor will review 1264  
the investigator’s assessment of causality and may agree or disagree.  Both the investigator’s and 1265  
Medical Monitor’s assessments will be recorded.  The Medical Monitor will have the final say in 1266  
determining the causality.  1267  
Adverse events that continue after the participant’s discontinuation or completion of the study will 1268  
be followed until their medical outcome is determined or until no further change in the condition 1269  
is expected.  1270  
 
 1271  
The outcome of each reportable adverse event will be classified by [CONTACT_3470]:  1272  
 RECOVERED/RESOLVED – The participant recovered from the AE/SAE without sequelae.  [ADDRESS_527626] the AE/SAE stop date.  1274  
 RECOVERED/RESO LVED WITH SEQUELAE – The event persisted and had stabilized [ADDRESS_527627] the AE/SAE stop date.  1276  
 FATAL – A fatal outcome is defined as the SAE that resulted in death.  Only the event that 1277  
was the cause of death should be r eported as fatal.  AEs/SAEs that were ongoing at the time of 1278  
death; however, were not the cause of death, will be recorded as “resolved” at the time of death.  1279  
 NOT RECOVERED/NOT RESOLVED (ONGOING) – An ongoing AE/SAE is defined as the 1280  
event was ongoing with  an undetermined outcome.  1281  
o An ongoing outcome will require follow -up by [CONTACT_418094] 1282  
final outcome of the AE/SAE.  1283  
o The outcome of an ongoing event at the time of death that was not the cause of death, will 1284  
be updated and recorded as “resolved” with the date of death recorded as the stop date.  1285  
 UNKNOWN – An unknown outcome is defined as an inability to access the participant or the 1286  
participant’s records to determine the outcome (for example, a participant that was lost to 1287  
follow-up). 1288  
All clinically significant abnormalities of clinical laboratory measurements or adverse events 1289  
occurring during the study and continuing at study termination should be followed by [CONTACT_941] 1290  
participant’s physician and evaluated with additional tests (i f necessary) until diagnosis of the [ADDRESS_527628] 1296  
the participant until the adverse event has resolved or stabilized.  1297  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 54 OF 76 
 
 Reportable Device Issues  1298  
All UADEs, ADEs, device complaints, and device malfunctions will be reported irrespective of 1299  
whether an adverse event occurred, except in the following circumstances.  1300  
The following device issues are anticipated and will not be reported on a Device Issue Form but 1301  
will reported as an Adverse Event if the criteria for AE reporting described above are met:  1302  
 Component disconnections  1303  
 CGM sensors lasting fewer th an the number of days expected per CGM labeling  1304  
 CGM tape adherence issues  1305  
 Pump infusion set occlusion not leading to ketosis  1306  
 Battery lifespan deficiency due to inadequate charging or extensive wireless communication  1307  
 Intermittent device component disconnect ions/communication failures not leading to system 1308  
replacement  1309  
 Device issues clearly addressed in the user guide manual that do not require additional 1310  
troubleshooting  1311  
 Skin reactions from CGM sensor placement or pump infusion set placement that do not meet [ADDRESS_527629] be reported to the Coordinatin g Center within 24 hours via completion of 1318  
the online serious adverse event form.  1319  
Other reportable adverse events, device malfunctions (with or without an adverse event), and 1320  
device complaints should be reported promptly by [CONTACT_418095], 1321  
but there is no formal required reporting period.  1322  
The Coordinating Center will notify all participating investigators of any adverse event that is 1323  
serious, related, and unexpected. Notification will be made within 10 days after the Coordinati ng 1324  
Center becomes aware of the event.  1325  
Each principal investigator [INVESTIGATOR_3411] -related adverse events and 1326  
abiding by [CONTACT_66716]/her Institutional Review Board or 1327  
Ethics Committee.  1328  
Upon receipt of a UADE report, the Sponsor will investigate the UADE and if indicated, report 1329  
the results of the investigation to the clinical centers ’ IRBs, and the FDA within 10 working days 1330  
of the Sponsor becoming aware of the UADE per 21CFR 812.46(b). The Medical Monitor must [ADDRESS_527630] receipt notice of the UADE.  1335  
In the case of a device system component malfunction (e.g. pump, CGM, control algorithm), 1336  
information will be fo rwarded to the responsible company by [CONTACT_418096], to be 1337  
handled by  [CONTACT_212414].  1338  
 Stoppi[INVESTIGATOR_2121]  1339  
 
 1340  
Rules for discontinuing study device use are described below.  1341  
 The investiga tor believes it is unsafe for the participant to continue on the intervention.  This 1342  
could be due to the development of a new medical condition or worsening of an existing 1343  
condition; or participant behavior contrary to the indications for use of the device  that imposes 1344  
on the participant’s safety  1345  
 The participant requests that the treatment be stopped  1346  
 Participant pregnancy  1347  
 Two distinct epi[INVESTIGATOR_3414]  1348  
 Two distinct severe hypoglycemia events as defined in section [IP_ADDRESS]  1349  
If pregnancy occurs, the participant will be discontinued from the study entirely. Otherwise, even 1350  
if the study device system is discontinued, the participant will be encouraged to remain in the study 1351  
through the final study visit.  1352  
 
 1353  
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or severe 1354  
hyperglycemia event (as defined in section [IP_ADDRESS] ), use of the study device system will be 1355  
suspended while the problem is diagnosed.  1356  
In addition, study activities could be similarly suspended if the manufacturer of any constituent 1357  
study devi ce requires stoppage of device use for safety reasons (e.g. product recall).  The affected 1358  
study activities may resume if the underlying problem can be corrected by a protocol or system 1359  
modification that will not invalidate the results obtained prior to su spension.  The study Medical 1360  
Monitor will review all adverse events and adverse device events that are reported during the study 1361  
and will review compi[INVESTIGATOR_27985] (generally timed to the review of 1362  
compi[INVESTIGATOR_418081]). The Medical Monitor may request suspension of study [ADDRESS_527631] (DSMB) will review compi[INVESTIGATOR_418082] d ata at periodic 1366  
intervals (typi[INVESTIGATOR_116511] 6 months). In addition, the DSMB will review all DKA and severe 1367  
hypoglycemia irrespective of relatedness to study device use, and all serious events (including 1368  
UADEs) related to study device use at the time of occ urrence. The DSMB also will be informed [ADDRESS_527632] modifications to the study protocol or suspension or outright 1371  
stoppage of the study if deemed necess ary based on the totality of safety data available. Details 1372  
regarding DSMB review will be documented in a separate DSMB document.  1373  
 Risks  1374  
The potential risks associated with use of the study device are described in section 1.3. 1375  
Additional risks are minor and/or infrequent and include:  1376  
 Pain, bruising, redness, or infection from blood draws  1377  
 Loss of confidentiality  1378  
 Stress from completing quality of life questi onnaires 1379  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 57 OF 76 
 Chapter 10:  Miscellaneous Considerations  [ADDRESS_527633] their personal 1384  
physician to change their prescribed personal insulin to lispro or aspart for the duration of the trial  1385  
in the case they are randomized to experimental arm  1386  
Treatment with any non -insulin glucose -lowering agent (including GLP -1 agonists, Symlin, DPP - 1387  
4 inhibitors, SGLT -2 inhibitors, biguanides, sulfonylureas and naturaceuticals) will not be 1388  
permitted.  1389  
The investigational study devices (t:slim X2 insulin pump, study CGM systems) must be removed 1390  
before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) or diathermy treatment. 1391  
Participants may continue in the trial after temporarily discontinuing use if requiring one of the 1392  
treatments above.   1393  
 Participant Withdrawal  1394  
Participation in the study is vo luntary, and a participant may withdraw at any time.  For  participants 1395  
who withdraw, their data will be used up until the time of withdrawal.  1396  
 Confidentiality  1397  
For security and confidentiality purposes, participants will be assigned an identifier that will 1398  
be used instead of their name.  Protected health information gathered for this study will be 1399  
shared  with the coordinating center, the Jaeb Center for Health Research in Tampa, FL.  1400  
De-identified participant information may also be provided to research site s involved in the study. 1401  
De-identified participant information may also be provided to Tandem for system evaluation 1402  
purposes.  1403  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 58 OF 76 
 Chapter 11:  Statistical Consideration  [ADDRESS_527634] tabulation of data by [CONTACT_1570] 1407  
(ie, for DSMB review).  The analysis plan synopsis in this chapter contains the framework of the 1408  
anticipated final ana lysis plan.  1409  
 Statistical Hypotheses  1410  
This study is an extension to children ages 6 -13 years old, of the Main  Protocol described in IDE 1411  
G180053, which includes N=168 children ages 14 and up and adults. Thus, t he primary outcome 1412  
for this study is identical to the Main protocol - CGM -measured % in range 70 -180 mg/dL.   1413  
The hypotheses for the primary outcome are:  1414  
a. Null Hypothesis : There is no difference in mean CGM -measured % in range 70 -180 mg/dL 1415  
over 16 weeks  between SC and CLC  1416  
b. Alternative Hypothesis : The mean C GM-measured % in range 70 -180 mg/dL over 16 1417  
weeks  is different for SC and CLC.  1418  
 Sample Size  1419  
Sample size has been computed for the primary outcome (CGM -measured % in rang e 70-180 1420  
mg/dL). Data from IDE G170267; Device Name: t:slim X2 with Control -IQ Technolog y; “Real - 1421  
Time Monitoring and Glucose Control During Winter -Sport Exercise in Youth with Type 1 1422  
Diabetes: The AP Ski Camp Continued” were used to calculate sample size specific to this age 1423  
group. In this study, which was completed in the winter of 2018, 24 school -aged children (6 -12 1424  
years) with type 1 d iabetes participated in a 3 -day ski camp ( ∼5 h skiing/day) , followed by [CONTACT_1629] 1425  
additional 72 hour at -home phase under parental supervision. Study participants were randomized 1426  
1:1 to  SAP and t:slim X2 with Control -IQ Technology. The data from the 72 -hour home p hase 1427  
was used for this sample size calculation – note that  the closed -loop control system and the age 1428  
range  of the participants are identical to those proposed in this application : 1429  
Results from home phase of G170267  Control IQ  SAP F p value  
Percent between 70 and 180mg/dl  71 ± 6.6  52.8 ± 13.[ADDRESS_527635] 1430  
deviation (after adjusting for the correlation between baseline and follow up) for time in range 70 - 1431  
180 mg/dL over the course of 6 months was 6% (95% CI 5% to 7%) for the CLC group and 7% 1432  
(95% CI 6% to 8%) for the SAP group.  1433  
A total sample size was  computed to be N=60 for the following assu mptions: (1) 3:1 [CLC: SC] 1434  
randomization, (2) 9 0% power, (3) a 10% absolute increase in % time in range 70 -180 mg/dL, (4) 1435  
an effe ctive SD of 10%, and (5) 2-sided type 1 error of 0.05. 1436  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 59 OF 76 
 The total sample size has been increased to N=100 to account for dropouts  and to increase the 1437  
number of participants who will be exposed to the CLC system for an enhanced safety and 1438  
feasibility assessment.   1439  
 Efficacy Outcome  Measures  1440  
 
 1441  
 CGM -measured % in range 70 -180 mg/dL  1442  
 
 1443  
[IP_ADDRESS]  Seco ndary Efficacy Endpoints Included in Hierarchical Analysis  1444  
The following secondary endpoints will be tested in a hierarchical fashion as described in  1445  
section  11.7.1 . 1446  
 CGM -measured % above 180 mg/dL  1447  
 CGM -measured mean glucose  1448  
 HbA1c at 16 weeks  1449  
 CGM -measured % below 70 mg/dL  1450  
 CGM -measured % below 54 mg/dL  1451  
 CGM -measured % above 250 mg/dL  1452  
 Glucose variability measured with the coefficient of variation (CV)  1453  
[IP_ADDRESS]  Other Secondary Efficacy Endpoints  1454  
The following endpoints are considered exploratory . Type 1 error for these endpoints will be 1455  
controlled using the false discovery rate (FDR) instead of the familywise error rate (FWER).   1456  
CGM -Measured:  1457  
 % in range 70 -140 mg/dL  1458  
 glucose variability measured with the standard deviation (SD)  1459  
 % <60 mg/dL  1460  
 low blood glucose index  1461  
 hypoglycemia events (defined as at least 15 consecutive minutes <70 mg/dL)  1462  
 % >300 mg/dL  1463  
 high blood glucose index  1464  
 % in range 70 -180 mg/dL  improvement fr om baseline to 16 weeks ≥5%  1465  
 % in range 70 -180 mg/dL  improvement from baseline to 16 weeks ≥10%  1466  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 60 OF 76 
 HbA1c:  1467  
 HbA1c <7.0% at 16 weeks  1468  
 HbA1c <7.5% at 16 weeks  1469  
 HbA1c improvement from baseline to 16 weeks >0.5%  1470  
 HbA1c improvement from baseline to 16 weeks >1.0%  1471  
 HbA1c relative improvement from baseline to 16 weeks >10%  1472  
 HbA1c improvement from baseline to 16 weeks >1.0% or HbA1c <7.0% at 16 weeks  1473  
Questionnaires  1474  
 Fear of Hypoglycemia Survey (HFS -II) – total score , 2 subscales  and 4 factor scores : 1475  
 Behavior (avoid ance and mai ntain high BG ) 1476  
 Worry  (helplessness and social consequences)  1477  
 Clarke Hypoglycemia Awareness Scores  1478  
 Problem Areas In Diabetes Survey (PAID)  1479  
 INSPI[INVESTIGATOR_367219]  1480  
 PedsQL Diabetes Module – total score and 5 subscales:  1481  
 Diabetes  1482  
 Treatment I  1483  
 Treatment II  1484  
 Worry  1485  
 Communication  1486  
 Pi[INVESTIGATOR_2272] (Parent only)  1487  
 System Usability Scale (SUS)  1488  
Other:  1489  
 Insulin  1490  
 Total daily insulin (units/kg)  1491  
 Basal: bolus insulin ratio  1492  
 Weight and Body Mass Index (BMI)  1493  
 
 1494  
Randomization is preceded by [CONTACT_418097] s of CGM run -in, which will be used in the calculation 1495  
of baseline CGM metrics.  For participants  who are eligible to skip the run -in, comparable 1496  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 61 OF 76 
 amount of CGM data from their own sensors will be taken before randomization visit to 1497  
calculate baseline CGM me trics. 1498  
CGM data starting from randomization visit through the 16-week  visit will be included in the 1499  
calculation of each CGM metric. Percentages in range 70 -180 mg/dL (and all other CGM -based 1500  
metrics) will be calculated giving equal weight to each CGM point  for each participant.  1501  
 Analysis Datasets and Sensitivity Analyses  1502  
All analyses comparing the CLC arm with SC arm will follow the intention -to-treat (ITT) 1503  
principle with each participant analyzed according to the treatment assigned by [CONTACT_17628]. 1504  
All ran domized participants will be included in the primary and secondary hierarchical analyses.  1505  
Safety outcomes will be reported for all enrolled participants, irrespective of whether the 1506  
participants was randomized or the study was completed.  1507  
 
 1508  
Per-protocol analys es will be performed for primary outcome and secondary hierarchical  1509  
outcomes  only if >5%  of participants  will be excluded:  1510  
 CLC arm: Closed loop mode active for at least 80% of the time  1511  
 SC arm: CGM use for at least 80% of the time  [ADDRESS_527636] two weeks of CGM data following the randomization visit.   The primary 1523  
analysis  will be replicated based on the recalculated outcome .  1524  
Missing Data  1525  
It is worth emphasizing that any statistical method for handling missing data makes a number of 1526  
untestable assumptions.   The goal will be to minimize the amount of missing data in this study so 1527  
that results and conclusions will not be sensitive to which statistical method is used. To that end, 1528  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 62 OF 76 
 sensitivity analyses will be performed to explore whether results are similar for primary analysis 1529  
when using different methods.   The following methods will be applied:  1530  
 Direct likelihood ( primary analysis described below) 1531  
 Rubin’s multiple imputation  1532  
 Multiple imputation with pattern mixture model   1533  
 Available cases only  1534  
 Analysis of the Primary Efficacy Endpoint  1535  
Summary statistics (mean ± SD or median (quartiles)) will be reported for the CGM -measured % 1536  
in range 70 -180 mg /dL and for differences from pre -randomization by [CONTACT_1570].  [ADDRESS_527637]-randomization period in 1538  
CGM -measured % in range 70 -180 mg/dL between two treatment arms will be compared using a 1539  
linear mi xed effects regression model while adjusting for baseline CGM -measured % in range 1540  
70-180 mg/dL, age, prior CGM and pump use, and clinical center (random effect). Missing data [ADDRESS_527638] statistical 1543  
method (e.g., non -parametric or MM estimation) will be used instead. It is expected that the 1544  
residual values for CGM -measured % in range 70 -180 mg /dL will follow an approximate normal [ADDRESS_527639] for the corresponding bas eline metric, age, prior 1549  
CGM and pump use, and clinical center (random effect).  1550  
 
 1551  
To preserve the overall type 1 error for selected key secondary endpoints, a hierarchical testing 1552  
procedure will be used. If the primary analysis for time  in range described above results in a 1553  
statistically significant result (p < 0.05), then testing (similar with the model described above 1554  
for the primary outcome) will proceed to the next outcome metric in the following order:  1555  
 CGM -measured % in range 70 -180 mg/dL (primary outcome)  1556  
 CGM -measured % above 180 mg/dL  1557  
 CGM -measured mean glucose  1558  
 HbA1c at 16 weeks  1559  
 CGM -measured % below 70 mg/dL  1560  
 CGM -measured % below 54 mg/dL  1561  
 CGM -measured % above 250 mg/dL  1562  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 63 OF 76 
  Glucose variability measured with the coefficient of variation (CV)  [ADDRESS_527640] until a non - 1564  
significant result (p ≥ 0.05) is observed, or all eight variables have been tested.  If a non - [ADDRESS_527641] a significant result so testing continues to the fifth variable (CGM % below  70 1569  
mg/dL).  The result is not significant for that fifth variable (p = 0.06) so testing stops.  No formal [ADDRESS_527642] in this example scenario.  1571  
HIERARCHICAL 
ORDER  OUTCOME 
VARI ABLE  TREATMENT  
ARM P -VALUE  SIGNIFICANT?  ACTION  
1st CGM % 70 -180 mg/dL 
(primary outcome)  0.[ADDRESS_527643] next variable  
2nd CGM % above  180 mg/dL  0.[ADDRESS_527644] next variable  
5th CGM % below 70 mg/dL  0.06 No Stop formal testing  
6th CGM % below 54 mg/dL  Not tested  Unknown  N/A 
7th  CGM %  above 250 mg/dL  Not tested  Unknown  N/A 
8th  Glucose CV  Not tested  Unknown  N/A 
Table [ADDRESS_527645] Results  1572  
Regardless of the results of the hierarchical testing, summary statistics appropriate to the 1573  
distribution will be tabulated by [CONTACT_418098].  A 95% confidence [ADDRESS_527646] failed to reach statistical sign ificance.  1578  
 
 1579  
CGM -Measured Outcomes  1580  
The analyses for the secondary CGM -measured outcomes will parallel those mentioned above 1581  
for the primary outcome.  For the binary CGM outcomes, risk -adjusted percentages by [CONTACT_3148] 1582  
group will be calc ulated from a logistic regression model.  1583  
HbA1c  1584  
Summary statistics (mean ± SD) will be reported for the central lab HbA1c at baseline, 16 weeks 1585  
and for differences from pre -randomization by [CONTACT_1570].  1586  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 64 OF 76 
 Change in HbA1c from baseline to 16 weeks will be compared between the two treatment arms 1587  
using a linear model while adjusting for baseline HbA1c, age, prior CGM and pump use, and 1588  
clinical center (random factor).  [ADDRESS_527647] for the same 1596  
factors mentioned above for the analysis with HbA1c as a continuous factor (i.e., baseline [ADDRESS_527648]).  [ADDRESS_527649] -randomization 1606  
safety events will be reported.    1607  
Safety analyses of the main study (randomized trial phase) will include  events  occurring on or [ADDRESS_527650] event date (whichever is later ). 1611  
Any pre -randomization adverse events will be tabulated separately and will include all 1612  
participants even if never randomized.  1613  
For the  following outcomes, mean ± SD or summary statistics appropriate to the distribution will 1614  
be tabulated by [CONTACT_418099] (main study phase only) will 1615  
be performed if there are enough events  (at least 5 events combined between the two treatment 1616  
groups) : 1617  
 Number of SH events and SH event rate per 100 person -years  1618  
 Number of DKA events and DKA event rate per 100 person -years  1619  
 Any adverse event’ rate per 100 person -years  1620  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 65 OF 76 
  Number of calendar days wit h any ketone level ≥1.0 mmol/L  1621  
 CGM -measured hypoglycemic events ( ≥15 minutes with glucose concentration <54 mg/dL)  1622  
 CGM -measured hyperglycemic events ( ≥15 minutes with glucose concentration >300 1623  
mg/dL)  1624  
 1625  
If enough events, the numbers of SH/DKA events  will be compared between the two treatment [ADDRESS_527651]. Th e amount of follow up will be included as an offset covariate to compare the 1629  
rates.  Similar analyses will be done for comparing any adverse event and number of calendar 1630  
days with ketone events between the two treatment groups, except that clinical center  will be the 1631  
only covariate to be adjusted in the model.  1632  
For CGM -measured hypoglycemia/hyperglycemia events , event rates per week will be compared 1633  
using similar linear mixed effects regression models as described above for the primary outcome.  1634  
 1635  
For both the  main study and extension phases, the f ollowing safety outcomes will be tabulated by 1636  
treatment group without a formal statistical comparison:  1637  
 Other serious adverse events (SAE)  1638  
 BG-measured hypoglycemic events ( days with at least one BG record  <54 mg/dL)  1639  
 BG-measured hyperglycemic events (days with at least one BG record  >350  mg/dL)  1640  
 Worsening of HbA1c from baseline to 16 weeks by >0.5%  1641  
 Investigational device related (intervention group only):  1642  
o Adverse device effects (ADE)  1643  
o Serious adverse device events (SADE)  1644  
o Unanticipated adverse device effects (UADE)  1645  
 1646  
 Intervention Adherence  1647  
The following tabulations and analyses will be performed by [CONTACT_418100] 1648  
intervention adherence for the study:  1649  
 Sensor use –percent time of use , overall and by 4 -weekly  1650  
 The dai ly frequency of downloaded BGM use  overall and by 4 -weekly  1651  
For CLC arm only, the following will be tabulated to assess adherence:  1652  
 % time in different operational modes - overall and by 4-weekly  1653  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 66 OF 76 
 
 Adherence and Retention Analyses  1654  
The following tabulations and  analyses will be performed by [CONTACT_418101] 1655  
adherence for the study:  1656  
 Number of protocol and procedural deviations per participant along with the number and 1657  
percentage of participants with each number of deviations  1658  
 Number of protocol a nd procedural deviations by [CONTACT_418102]  1659  
 Flow chart accounting for all participants at all scheduled visits and phone contacts post 1660  
treatment initiation to assess visit and phone completion rates  1661  
 Number of and reasons for unsched uled visits and phone calls  1662  
 Number of participants who stopped treatment and reasons  1663  
 Baseline Descriptive Statistics  1664  
Baseline demographic and clinical characteristics of the cohort of all randomized participants 1665  
will be summarized in a table using summary statistics appropriate to the distribution of each 1666  
variable. Descriptive statistics will be displayed by [CONTACT_1570].  1667  
Will include:  1668  
 Age 1669  
 HbA1c  1670  
 Gender  1671  
 Race /Ethnicity  1672  
 Family income, education, and/or insurance status  1673  
 Insulin method before enrollment (pump  vs. MDI)  1674  
 CGM use before enrollment  1675  
 Diabetes duration  1676  
 BMI (height and weight)  1677  
 C-peptide  1678  
 Participant -reported number of SH and DKA 12 months prior to the start of the study  1679  
 Device Issues  1680  
The following tabulations and analyses will be performed by [CONTACT_418103] 1681  
issues:  1682  
 Device malfunctions requiring study team contact [CONTACT_91120]  1683  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 67 OF 76 
  Sensor performance metrics (difference, absolute relative difference, and International 1684  
Organization for Standardization criteria) – if applica ble, by [CONTACT_91121].  1685  
 Rate of different failure events and alarms per 24  hours  recorded by [CONTACT_418104] -IQ system – 1686  
overall and by [CONTACT_24473]  1687  
 Planned Interim Analyses  1688  
All above efficacy and safety  analys es will be conducted  after all subjects completed the primary 1689  
study phase . No sample size re -estimation will be needed for the extension phase.  The data may 1690  
be used for PMA, with no interruption  on the extension phase .  1691  
In addition, t he DSMB will review safety data at intervals, with no formal stoppi[INVESTIGATOR_418083] 1692  
than the guidelines provided in the participant -level and study -level stoppi[INVESTIGATOR_3418] (as defined 1693  
in Section 9.5 of the protocol).  [ADDRESS_527652] oratory analyses, the primary outcome  (time 70 -180 mg/dL) , % time <70 mg/dL and HbA1c [ADDRESS_527653].  1699  
Interpretation of subgroup analyses will depend on whether the overall analysis demonstrates a 1700  
significant treatment group difference. In the absence  of such an overall difference and if 1701  
performed, subgroup analyses will be interpreted with caution. For continuous variables, results 1702  
will be displayed in subgroups based on cutpoints although the analysis will utilize the variable as 1703  
continuous, except f or age which will be analyzed both as a continuous variable and in two age 1704  
groups. If there is insufficient sample size in a given subgroup, the cutpoints for continuous 1705  
measures may be adjusted per the observed distribution of values. Cutpoint selection f or display 1706  
purposes will be made masked to the outcome data.  1707  
 Baseline HbA1c  1708  
 Baseline CGM time spent < 70 mg/dL  1709  
 Baseline CGM time spent >180 mg/dL  1710  
 Baseline CGM time 70 -180 mg/dL  1711  
 Device use before the enrollment: pump/MDI, CGM/no CGM, and combinations of bot h 1712  
 Age 1713  
 Sex 1714  
 Race / Ethnicity  1715  
 Clinical center  1716  
 BMI (Height and weight)  1717  
 Family i ncome, education, and/or insurance status  1718  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 68 OF 76 
  C-peptide level  1719  
 Multiple Comparison/Multiplicity  1720  
Primary Analysis  1721  
Since there will be a single comparison for the primary outcome (CGM -measu red % 70 -180 1722  
mg/dL), no adjustment is needed.  1723  
Secondary Hierarchical Analyses  1724  
The hierarchical testing procedure described above in section 11.7.1  will be used to c ontrol the 1725  
overall type 1 error for the primary outcome plus seven key secondary outcomes identified above.  1726  
All Other Secondary Analyses  1727  
For all above -mentioned secondary analyses, the false discovery rate will be controlled using the 1728  
adaptive Benjamini -Hochberg procedure.  1729  
 Exploratory Analyses  1730  
In addition to the analysis for the CGM -measured  endpoints described earlier, separate analyses 1731  
will be conducted for daytime and nighttime.  1732  
The CGM -measured analyses will be replicated with only CGM data when the closed -loop was 1733  
active for the CLC group. The CGM data for the SC group will be the same as mentioned above  1734  
in the CGM Metrics Calculation section  11.4.3 . 1735  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 69 OF 76 
 Chapter 12:  Data Collection and Monitoring  1736  
 Case Report Forms and Device Data  1737  
The main study data are collected through a combination of electronic case report forms 1738  
(CRFs)  and electronic devi ce data files obtained from the study software and individual hardware [ADDRESS_527654] s will be destroyed without the written 1751  
consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 1752  
investigator when these documents no longer need to be retained.  1753  
 Quality Assurance and Monitoring  1754  
Designated personnel fro m the Coordinating Center will be responsible for maintaining quality 1755  
assurance (QA) and quality control (QC) systems to ensure that the clinical portion of the trial is 1756  
conducted and data are generated, documented and reported in compliance with the proto col, Good 1757  
Clinical Practice (GCP) and the applicable regulatory requirements.  Adverse events will be 1758  
prioritized for monitoring.  1759  
A risk -based monitoring (RBM) plan will be developed and revised as needed during the course 1760  
of the study, consistent with the  FDA “Guidance for Industry Oversight of Clinical Investigations 1761  
— A Risk -Based Approach to Monitoring” (August 2013).  Study conduct and monitoring will 1762  
conform with 21 Code of Federal Regulations (CFR) 812.  [ADDRESS_527655] eteness of the key clinical center data.  Elements of the RBM may include:  1767  
 Qualification assessment, training, and certification for clinical centers and clinical center 1768  
personnel  1769  
 Oversight of Institutional Review Board (IRB) coverage and informed consent procedures  1770  
 Central (remote) data monitoring: validation of data entry, data edits/audit trail, protocol 1771  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 70 OF 76 
 review of entered data and edits, statistical monitoring, study closeout  1772  
 On-site monitoring (site visits): source data verification, site visit report  1773  
 Agent/Device accountability  1774  
 Communications with clinical center staff 1775  
 Participant retention and visit completion  1776  
 Quality control reports  1777  
 Management of noncompliance  1778  
 Documenting monitoring activities  1779  
 Adverse event reporting and monitoring  [ADDRESS_527656] and p rogress of the 1783  
study.  1784  
 Protocol Deviations  1785  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or procedure 1786  
requirements.  The noncompliance may be either on the part of the participant, the investigator, or 1787  
the clinical center  staff.  As a result of deviations, corrective actions are to be developed by [CONTACT_941] 1788  
clinical center and implemented promptly.  1789  
The clinical center PI/study staff is responsible for knowing and adhering to the IRB requirements.  1790  
Further details about the handli ng of protocol deviations will be included in the monitoring plan.  1791  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 71 OF 76 
 Chapter 13:  Ethics/Protection of Human Participants  [ADDRESS_527657]  1793  
The investigator will ensure that this study is conducted in full conformity with Regulations for 1794  
the Protection of Human Participants of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 1795  
CFR Part 56, and/or the ICH E6.  1796  
 Institutional Review Boards  1797  
The protocol, informed consent form(s), recruitment materials, and all participant materials will [ADDRESS_527658] be obtained before any participant is enrolled.  Any amendment to the protocol will 1800  
require review and approval by [CONTACT_3484] .  All 1801  
changes to the consent form will be IRB approved; a determination will be made regarding whether 1802  
previously consented participants need to be re -consented.  1803  
 Informed Consent Process  1804  
 
 1805  
Informed consent is a process t hat is initiated prior to the individual’s agreeing to participate in the 1806  
study and continues throughout the individual’s study participation.  Extensive discussion of risks [ADDRESS_527659] all documents and records required to be 1824  
maintained by [CONTACT_093], including but not limited to, medical records (offic e, clinic, or 1825  
hospi[INVESTIGATOR_307]) for the participants in this study.  The clinical center  will permit access to such records.  1826  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 72 OF 76 
 The study participant’s contact [CONTACT_418105] 1827  
internal use during the study.  At the end of the study, all records will continue to be kept in a 1828  
secure location for as long a period as dictated by [CONTACT_46202].  1829  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, 1830  
will be transmitted to and stored at the Jaeb Center for Health Research and the University of 1831  
Virginia Center for Diabetes Technology.  This will not include the participant’s contact [INVESTIGATOR_1660] [ADDRESS_527660] protected.  At the 1835  
end of the study, all study datab ases will be de -identified and archived at Jaeb Center for Health 1836  
Research and the University of Virginia Center for Diabetes Technology. Permission to transmit 1837  
data will be included in the informed consent.  1838  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 73 OF 76 
 Chapter 14:  References  1839  
1. Kovatchev, B.P., Breton , M.D., Keith -Hynes, P.T., Patek, S.D. The Diabetes Assistant (DiAs) 1840  
– Unified platform for monitoring and control of blood glucose levels in diabetic patients; [ADDRESS_527661]/US12/[ZIP_CODE], 2012.  1842  
2. Keith Hynes, P., Guerlain, S., Mize, L.B., Hughes Karvetski, C., Khan, M. , McElwee Malloy, 1843  
M. & Kovatchev, B.P. DiAs user interface: A patient -centric interface for mobile artificial 1844  
pancreas systems. J Diabetes Sci Technol, 7, 1416 –1426 (2013). PMID: [ADDRESS_527662], J., Robert, A., Ben Brahim, N., Keith Hynes, P., Farret, A., Pelletier, M.J., Buckingham, 1846  
B., Breton, M., Kovatchev, B.P. & Renard, E. DiAs web monitoring: A real -time remote 1847  
monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Technol, 7, 1848  
1427 –1435. (2013). PMID: [ADDRESS_527663], J. The Diabetes Assistant: A smartphone -based 1850  
system for real -time control of blood glucose. Electronics 2014, 3, 609 -623; 1851  
doi:10.3390/electronics3040609  [ADDRESS_527664], J., Bruttomesso, D., 1854  
Del Favero, S., Visentin, R., Filippi, A., Scotton, R., Avogaro, A. & Doyle III, F.J. Feasibility 1855  
of outpatient fully integrated closed -loop control: First studies of wearable artificial pancreas. 1856  
Diabetes Care, 36, 1851 -1858 doi: 10.2337/dc12 -1965 (2013). PMID: 23801798, PMCID: [ADDRESS_527665], J., Bruttomesso, D., Del 1860  
Favero, S., Boscari, F., Galasso, S., Avogaro, A., Magni, L., Di Palma, F., Toffanin, C., 1861  
Messori, M., Dassay, E., Doyle, F. III. Safety of outpatient closed -loop cont rol: First 1862  
randomized crossover trials of a wearable artificial pancreas. Diabetes Care, 37,  1789 -1796 1863  
doi: 10.2337/dc13 -2076 (2014). PMID: 24929429, PMCID: PMC4067397  [ADDRESS_527666], J., Caswell, K., Wilson, D., Harris, B. , 1865  
Clinton, P., Kovatchev, B.P., Buckingham, B.A. Remote glucose monitoring in camp setting 1866  
reduces the risk of prolonged nocturnal hypoglycemia. Diabetes Technol Ther, 16, 1 -7 1867  
doi:10.1089/dia.2013.0139 (2013). PMID: [ADDRESS_527667], J., Wilson, D.M., Kovatchev, B.P., Buckingham, B.A. Overnight 1870  
glucose control with an automated, unified safety system in children and adolescents with type 1871  
1 diabetes at diabetes camp. Diabetes Care, 37, doi: 10.2337/dc14 -0147 (2014). PMID: 1872  
24879841, PMCID: PMC4179507  [ADDRESS_527668], E., 1876  
Magni, L., for the AP@home consortium. 2 month evening and night closed -loop glucose 1877  
control in patients with Type 1 Diabetes under free -living conditions: A randomised crossover 1878  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 74 OF 76 
 trial. Lancet Diabetes Endocrinol, 3(12):939 -47 dx.doi.org/10.1016/S2213 -8587(15)[ZIP_CODE] -6 1879  
(2015).  [ADDRESS_527669] New Year’s Night on closed -loop control (CLC) at home: Case reports 1884  
from a mu lti-center international trial of long -term 24/7 CLC. 2015 -A-4763 -Diabetes. 1885  
American Diabetes Association 75th Scientific Sessions, [LOCATION_011], MA, presentation 223 –OR. 1886  
12. Kovatchev BP. JDRF Multi -Center 6 -Month Trial of 24/7 Closed -Loop Control. Advanced 1887  
Technol ogies and Treatments for Diabetes (ATTD), Plenary Session, Milan, Italy, 2016.  1888  
13. Kovatchev, B.P. Closed -loop control modalities in type 1 diabetes: Efficacy and system 1889  
acceptance. Advanced Technologies and Treatments for Diabetes (ATTD), Paris, [LOCATION_009], 1890  
2015.  1891  
14. Del Favero S. A multicenter randomized cross -over Italian pediatric summer camp: AP vs SAP 1892  
in 5-8 year old children. Advanced Technologies and Treatments for Diabetes (ATTD), 1893  
Plenary Session, Milan, Italy, 2016.  1894  
15. Cherñavvsky, D. et al. Closed -loop control during extended winter -sport exercise in youth with 1895  
T1DM: Results from the first AP ski camp. ATTD Data Club Session, Milan, (2016).  1896  
16. Chernavvsky, D.R., DeBoer, M.D., Keith -Hynes, P., Mize, B., McElwee, M., Demartini, S., 1897  
Dunsmore, S.F., Wakeman, C., Kovatc hev, B.P., Breton, M.D. Use of an artificial pancreas 1898  
among adolescents for a missed snack bolus and an underestimated meal bolus. Pediatric 1899  
Diabetes, doi:10.1111/pedi.[ZIP_CODE] (2014). PMID: 25348683  1900  
17. Brown, S.A., Kovatchev, B.P., Breton, M.D., Anderson, S.M.,  Keith -Hynes, P., Patek, S.D., 1901  
Jiang, B., Ben Brahim, N., Vereshchetin, P., Bruttomesso, D., Avogaro, A., Del Favero, S., 1902  
Boscari, F., Galasso, S., Visentin, R., Monaro, M., Cobelli, C. Multinight “bedside” 1903  
closed -loop control for patients with type 1 diab etes. Diabetes Technol Ther 17(3), 1904  
doi:10.1089/dia.2014.0259 (2015). PMID: 25594434, PMCID: PMC4346235  [ADDRESS_527670] WV, Cefalu WT, Cobelli C. The Artificial Pancreas in 2016: 1906  
A Digital Treatment Ecosystem for Diabetes. Diabetes Care 2016; 39:11 23-27. PMID: 1907  
27330124  1908  
19. Del Favero S, Boscari F, Messori M, Rabbone I, Bonfanti R, Sabbion A, IaFusco D, Schiaffini 1909  
R, Visentin R, Calore R, Moncada YL, Galasso S, Galderisi A, Vallone V, Di Palma F, Losiouk 1910  
E1, Lanzola G1, Tinti D, Rigamonti A, Marigliano M , Zanfardino A, Rapi[INVESTIGATOR_9384] N, Avogaro A, 1911  
Chernavvsky D, Magni L, Cobelli C, Bruttomesso D. Randomized Summer Camp Crossover 1912  
Trial in 5 - to 9-Year -Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and 1913  
Safe. Diabetes Care. 2016;39:1180 -5. PMID: [ADDRESS_527671] J, Visentin R, Calore R, 1915  
Toffanin C, Di Palma F, Lanzola G, Galasso S, Avogaro A, Keith -Hynes P, Kovatchev BP, 1916  
Del Favero S., Cobelli C, Magni L, DeVries HJ. AP@home Consortium. Day and night closed 1917  
loop glucose control in patients with type 1 diabetes under free -living conditions: comparison 1918  
 
 
 
DCLP5  V2.5_P EDIATRIC _CLINICAL PROTOCOL _CLEAN _09O CT2019  PAGE 75 OF 76 
 of a single -arm, 1 -month experience to results of a previously reported feasibility study of 1919  
evening and night at home. Diabetes Care 2016; 39:1151 -60. PMID: [ADDRESS_527672] J, Ly TT, 1923  
Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, and 1924  
Kovatchev BP. Multinational home use of closed -loop control is safe and effective. 1925  
Diabetes  Care 2016; 39:1143 -1150. PMID: [ADDRESS_527673], Topchyan K, Kovatchev BP, Francis GL, Breton MD. Heart 1927  
rate informed artificial pancreas system enhances glycemic control during exercise in 1928  
adolescents with T1D. Pediatr Diabetes. 2016; doi: 10.1111/pedi.[ZIP_CODE]. PMID: [ADDRESS_527674], Bevier WC, Bradley PK, 1931  
Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Ly TT, Shanmugham S, 1932  
Dassau E, Kollman C, Lum JW, Beck RW, f or the Control to Range Study Group. Feasibility 1933  
of Long -Term Closed -Loop Control: A Multicenter 6 -Month Trial of 24/7 Automated Insulin 1934  
Delivery. Diabetes Technol Ther 2017; 19: 18 -24. doi:10.1089/dia.2016.0333. PMID: [ADDRESS_527675]. Performance of an Artificial Pancreas System for Young 1938  
Children with Type 1 Diabetes. Diabetes Technol Ther 2017; 19, DOI: 10.1089/dia.2016.0424. 1939  
PMID: [ADDRESS_527676], Forlenza GP, DeBoer MD, Robic J, Wadwa RP, Messer LH,  1941  
Kovatchev BP, Maahs DM. Closed Loop Control During Intense Prolonged Outdoor Exercise 1942  
in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. Diabetes Care 2017 1943  
Aug; dc170883 . https://doi.org/10.2337/dc17 -0883  1944  
26. Ly TT, Gallego PH, Davis EA, Jones TW : Impaired Awareness of Hypoglycemia in a 1945  
Population -Based Sample of Children and Adolescents With Type 1 Diabetes . Diabetes Care 1946  
32(10):[ADDRESS_527677] JA, Vajda KA, Nyer M, Clarke WL, Gonder -Frederick LA, : Understanding the [ADDRESS_527678] of Fear of Hypoglycemia in Pediatric Type 1 Diabetes . J Pediatr Psychol  39(10) : 1949  
1115 -1125 , 201 4 1950  
28. Markowitz JT, Volkening LK, Butler DA, Antisdel -Lomaglio J, Anderson BJ, Laffel LM. Re - 1951  
examining a  measure of diabetes -related burden in parents of young people with Type 1 1952  
diabetes: the Problem Areas in Diabetes Survey - Parent Revised version (PAID -PR). Diabet 1953  
Med. 2012;29(4):526 –530. doi:10.1111/j.1464 -5491.2011.[ZIP_CODE].  1954  
29. Varni, J. W., Delamater, A.M.,  Hood, K.K., Raymond, J.K., Chang, N.T., Driscoll, K.A., 1955  
Wong, J.C., Yi -Frazier, J.P., Grishman, E.K., Faith, M.A., Corathers, S.D., Kichler, J.C., 1956  
Miller, J.L., Doskey, E.M.,  Aguirre, V.P., Heffer, R.W., & Wilson, D. P. (in press). Pediatric 1957  
Quality of Li fe Inventory (PedsQL) 3.2 Diabetes Module for youth with Type 2 diabetes: [ADDRESS_527679]:  1960  
Assessing patient ‐reported outcomes for automated insulin delivery systems: the psychometric 1961  
properties of the INSPI[INVESTIGATOR_418084] . Diabet. Med.  00: 1 – 9 ( 2019)  [ADDRESS_527680] , Monk TH , Berman SR , Kupfer DJ : The Pi[INVESTIGATOR_418085] 1963  
Quality Index: a new instrument for psychiatric practice and research.  Psychiatry Res.  1989 1964  
May;28(2):193 -213 1965  
32. Brown S, Raghinaru D, Emory E, Kovatchev B: First Look at Control -IQ: A New -Generation [ADDRESS_527681] 2018, dc181249; DOI: 10.2337/dc18 - 1967  
1249. PMID: 30305346  1968  
33. Ekhlaspour L, Wadwa RP, Chernavvsky D, Forlenza GP, Messer L, Town M, Swanson V, 1969  
Maahs DM, Kovatchev B, B uckingham B, Breton M: Artificial Pancreas (AP) Ski Camp 2018: 1970  
Successful Use of the Tandem Control -IQ AP System in Adolescents and Children During 1971  
Winter Sports and at Home (abstract). Pediatric Diabetes 2018;17  1972  